Ohio State Navbar

Directory

Guido Marcucci, MD


Staff photo

460 W. 12th Ave.
898 Biomedical Research Tower
Columbus, OH 43210

Phone: (614) 366-2261

Email: marcucci.1@osu.edu

 

Current OSU Appointments

Professor, Hematology

Professor, SBS-Molec Vir, Imm & Med Gen

Professor, Pharm CBO/Coll

Physician, FGP-Hematology

 

Biographical

Dr. Marcucci is a tenured Professor of Medicine, Professor of Pharmaceutics, and Professor of Microbiology, Immunology and Cancer Genetics at OSU. Dr. Marcucci earned his MD degree from the Catholic University of Sacred Heart in Rome, Italy, and completed his internal medicine internship and residency at the SUNY at Buffalo. This was followed by a two-year medical oncology fellowship at the Roswell Park Cancer Institute Buffalo, NY and one year of NIH-T32 medical oncology fellowship at OSU. Since July 1998, Dr. Marcucci has been an Assistant Professor, an Associate Professor (with tenure) and now a Professor in the Division of Hematology at OSU. Dr. Marcucci's work focuses on the pathogenesis, treatment and prognostic assessment of AML. 1) Pathogenesis of AML. In this area, Dr. Marcucci focus has been predominately on the role of aberrant epigenetics in myeloid leukemogenesis in three main subtypes of AML: core binding factor (CBF), cytogenticallly normal (CN) and MLL gene aberration-driven AML. He was the first to report the direct interaction of DNA methyltransferase I (DNMT1) and the fusion protein AML1/ETO encoded by the fusion gene resulting from the t(8;121) in AML. This interplay is likely to mediate the leukemogeneic activity of the fusion gene and cause a block in hematopoietic differentiation in the leukemic blasts. This effort has carried forth through other work in which he has focused on the therapeutic inhibition of epigenetic silencing using agents that target DNA methyltransferase and/or histone deacetylase co-repressor complexes. His recent laboratory work was the first to identify the importance of NF-κB in the regulation of DNMT1 and the ability of bortezomib to promote hypomethylation and re-express genes silenced in AML. More recently, Dr. Marcucci has also demonstrated how microRNAs can be both effectors and targets of aberrant epigenetic in AML. He has shown that microRNA 29b targets and downregulates DNA methyltransferases and their transcription factors (i.e., Sp1) thereby resulting in promoter hypomethylation and re-expression of genes that play pivotal roles in normal hematopoietic differentiation and apoptosis. Finally, in collaboration with Dr. Caligiuri, Dr. Marcucci has worked on the pathogenesis of MLL-driven AML, demonstrating the pivotal of the epigenetic silencing of the MLL wild type allele in blocking apoptosis and sustaining leukemogenesis in MLL partial tandem duplication AML. The work in this are has been funded through NCI K08 and other NCI-funded grants. 2) Experimental Therapeutics in AML. Several clinical trials are now moving forward based of Dr. Marcucci's preclinical work in AML. Phase I and II clinical trials utilizing epigenetic targeting agents (i.e.,decitabine, azacitidine, depsipeptide, valproic acid, bortezomib) in AML have been designed and conducted under the supervision of Dr. Marcucci. In addition to these efforts, Dr. Marcucci has been active in pursuing RNA-based therapies utilizing antisense oligoeoxynucleotides including G3139, GTI2020, and MG98. Phase I, II and III clinical trials utilizing these agents in AML have been designed and conducted under the supervision of Dr. Marcucci. Currently, in collaboration with Dr. Kenneth Chan and Dr. Robert Lee from the College of Pharmacy , Dr. Marcucci is actively pursuing targeting nanoparticle formulation and intracellular pharmacokinetics of oligonucleotide compounds in AML. Finally, based on the report that mutations of the tyrosine kinase receptor KIT is associated with poor prognosis in CBF AML, an otherwise favorable cytogenetic group by Drs. Paschka, Marcucci and Bloomfield, Dr. Marcucci will lead a trial in Cancer and Leukemia Group B (CALGB) utilizing the tyrosine kinase inhibitor dasatininb in combination with chemotherapy for CBF AML. Dr. Marcucci preclinical and clinical activity in experimental therapeutics have been funded through NCI RO1 (2) and R21(3). 3) Prognostication in AML. Dr. Marcucci in collaboration with Dr. Bloomfield, leads one of the most world renewed groups focusing on AML prognostication using single gene mutations and/or expression and genome-wide RNA and microRNA expression profiling. This work sets the basis for using molecular markers to guide treatment in AML according to the risk for poor outcome, thereby introducing the concept of "personalized therapy" in AML. This work has culminated in 2008 with the publication in the New England Journal of Medicine (Marcucci first author) of a paper where integration of cytogenetic and mutational analyses with microRNA and gene expression profiles identified novel molecular/prognostic subsets of AML, where genes involved with native immunity are overexpressed to sustaining leukemogenesis and may be targeted therapeutically. Because his expertise in the basic and translational molecular biology applied to AML, Dr. Marcucci has become a cadre member of the CALGB Leukemia Correlative Science Committee , and on behalf of this Committee he oversees the molecular screening to determine protocol eligibility for the US AML patients for the CALGB treatment trials that target specific molecular subsets of AML. In addition he is the chair/co-Chair of at least 4 different non-clinical protocols for molecular characterization of AML within CALGB. The work of Dr. Marcucci in the area of AML prognostication has produced more than 40 publications. This work has been funded through NCI U10, R21 and private foundations.

Certifications

1989 - present FMGEMS: Educational Commission for Foreign Medical Graduates
1992 - present FLEX: Federation of Licensing Examination Commonwealth
1997 - present Ohio State License: American Board of Medical Oncology
2007 - present Medical Oncology: American Board of Medical Oncology
1993 - 1995 Pennsylvania State License: American Board of Medical Oncology
1995 - 1997 New York Sate License: American Board of Medical Oncology
1993 - 2003 Internal Medicine: American Board of Internal Medicine
1997 - 2007 Medical Oncology: American Board of Medical Oncology
 

Chapters in Books

Marcucci G, Strout MP, Caligiuri MA, Bloomfield CD. "Core binding factor (CBF) and ALL1 (MLL)-associated adult primary acute myeloid leukemia: biology and clinical implications of two major genetic subtypes." In ASCO Educational Book. -. n/a: n/a, January 1998.

Marcucci G, Caligiuri MA, Bloomfield CD. "Core Binding Factor (CBF) Primary Acute Myeloid Leukemia: Biology and Clinical Implications.." In Medscape Oncology. -. n/a: n/a, January 2000.

Marcucci G and Caligiuri MA. "Antisense and gene transfer as therapeutic strategies in acute and chronic leukemia. Leukemia 7/e, Henderson EA et al." In WB Saunders. -. New York: n/a, January 2000.

Marcucci G and Caligiuri MA. "Minimal Residual Disease in Acute Myeloid Leukemia:RT-PCR-based Studies of Fusion Transcripts." In Humana Press. -. n/a: n/a, January 2001.

 

Conferences

Paschka,Peter; Marcucci,Guido; Ruppert,Amy,S; Mrozek,Krzysztof; Chen,Hankui; Kittles,Rick,A; Vukosavljevic,Tamara; Perrotti,Danilo; Vardiman,James,W; Carroll,Andrew,J; Kolitz,Jonathan,E; Larson,Richard,A; Bloomfield,Clara,D. "Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B study." In JOURNAL OF CLINICAL ONCOLOGY. (August 2006). 3904-3911.

Ali,Naeem,A; O'Brien,James,M; Blum,William; Byrd,John,C; Klisovic,Rebecca,B; Marcucci,Guido; Phillips,Gary; Marsh,Clay,B. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." In CANCER. (July 2007). 96-102.

Blum,William; Klisovic,Rebecca,B; Hackanson,Bjoern; Liu,Zhongfa; Liu,Shujun; Devine,Hollie; Vukosavljevic,Tamara; Huynh,LeNguyen; Lozanski,Gerard; Kefauver,Cheryl; Plass,Christoph; Devine,Steven,M; Heerema,Nyla,A; Murgo,Anthony; Chan,Kenneth,K; Grever,Michael,R; Byrd,John,C; Marcucci,Guido. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia." In JOURNAL OF CLINICAL ONCOLOGY. (September 2007). 3884-3891.

Garzon,Ramiro; Volinia,Stefano; Liu,Chang-gong; Fernandez-Cymering,Cecilia; Palumbo,Tiziana; Pichiorri,Flavia; Fabbri,Muller; Coombes,Kevin; Alder,Hansjuerg; Nakamura,Tatsuya; Flomenberg,Neal; Marcucci,Guido; Calin,George,A; Kornblau,Steven,M; Kantarjian,Hagop; Bloomfield,Clara,D; Andreeff,Michael; Croce,Carlo,M. "MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia." In BLOOD. (March 2008). 3183-3189.

Blum,William; Marcucci,Guido. "New approaches in acute myeloid leukemia." In BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. (March 2008). 29-41.

Neubauer,Andreas; Maharry,Kati; Mrozek,Krzysztof; Thiede,Christian; Marcucci,Guido; Paschka,Peter; Mayer,Robert,J; Larson,Richard,A; Liu,Edison,T; Bloomfield,Clara,D. "Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: A Cancer and Leukemia Group B study." In JOURNAL OF CLINICAL ONCOLOGY. (October 2008). 4603-4609.

Liu,Zhongfa; Liu,Shujun; Xie,Zhiliang; Pavlovicz,Ryan,E; Wu,Jiejun; Chen,Ping; Aimiuwu,Josephine; Pang,Jiuxia; Bhasin,Deepak; Neviani,Paolo; Fuchs,James,R; Plass,Christoph; Li,Pui-Kai; Li,Chenglong; Huang,Tim,HM; Wu,Lai-Chu; Rush,Laura; Wang,Hongyan; Perrotti,Danilo; Marcucci,Guido; Chan,Kenneth,K. "Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide." In JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. (May 2009). 505-514.

Rodriguez,Benjamin,AT; Frankhouser,David; Murphy,Mark; Trimarchi,Michael; Tam,Hok-Hei; Curfman,John; Huang,Rita; Chan,Michael,WY; Lai,Hung-Cheng; Parikh,Deval; Ball,Bryan; Schwind,Sebastian; Blum,William; Marcucci,Guido; Yan,Pearlly; Bundschuh,Ralf. "Methods for high-throughput MethylCap-Seq data analysis." In BMC GENOMICS. (October 2012). S14-.

 

Degrees

1986 M.D., Catholic University of the Sacred Heart

 

Editorial Activities

present Journal of Clinical Oncology
present European Journal of Hematology
present Cancer
present American Journal of Hematology
present Leukemia & Lymphoma
present Hematological
present Experimental Hematology
present Cancer Research
present British Journal of Hematology
present Blood
present Biotechniques
present Leukemia Research
present Nature of Medicine
present British Journal of Cancer
2008 - present Hematologica
2008 Seminars in Oncology
 

Honors

1986 Summa Cum Laude. Catholic University of Sacred Heart.
1989 Summa Cum Laude. Catholic University of Sacred Heart.
1990 Regione Lazio. Regione Lazio Internal Medicine.
1993 - 1994 Clinical Medical Oncology Fellowship. Clinical Fellowship.
1996 - 1997 T32-Fellowship. National Cancer Institute.
1998 - 1999 Institution Seed Funding. America Cancer Society.
1999 - 2000 Director's Cancer Enhancement Award. Comprehensive Cancer Center.
2001 - 2007 NIH KO8 Carreer Development Award. National Cancer Institute.
2003 - 2005 Cancer and Leukemia Group B Jounior Faculty Research Award. Cancer and Leukemia Group B.
2007 - 2010 Cadre Member, Leukemia Corelative Sciences Committee. CALGB.
2008 Director, Leukemia Tissue Bank. Comprehensive Cancer Center.
2010 Associate Director for Translational Research. Comprehensive Cancer Center.
2010 Associate Director for Research. Division of Hematology.
2010 Cadre Member,Leuemia Committee. CALGB.
2010 Chairman Leukemia Correlative Scences Committee. CALGB.
2011 John B. and Jane T. McCoy Chair in Cancer Research. Comprehensive Cancer Center.
2011 Donald V. Unverferth Research Award. Department of Internal Medicine.
2012 Charles Austin Doan Chair of Medicine. The Ohio State University.
 

Journal Articles

Rusciani L, Romagnoli A, Marcucci G, Bono R, Fazii P. "Bullous pemphigoid and lung cancer." Giorn Ital Chir Dermatol Oncol. Vol. 3, (January 1988.): 112-4.

Marcucci G, Rusciani L, Rotoli M. "Penoscrotal edema and Crohn disease." Giorn Ital Dermat Ped. Vol. 1, (January 1989.): 4-7.

Marcucci G, Caligiuri MA, Bloomfield CD. "Defining the absence of minimal residual disease by reserve transcription polymerase chain reaction in CBFB-MYH11-associated acute myeloid leukemia." Blood. Vol. 90, no. 12. (January 1997.): 5022-5024.

Marcucci,G; Caligiuri,M,A; Bloomfield,C,D. "Defining the ''absence'' of the CBF beta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: A call for definitions." BLOOD. Vol. 90, no. 12. (December 1997.): 5022-5024.

Marcucci G, Stout MP, Bloomfield CD, Caligiuri MA. "Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL 1 fusion transcripts." Cancer Res. Vol. 58, no. 4. (February 1998.): 790-793.

Marcucci G, Livak KJ, Bi W, Strout MP, Bloomfield CD, Caligiuri MA. "Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay." Leukemia. Vol. 12, no. 9. (September 1998.): 1482-1489.

Strout MP, Marcucci G, Bloomfield CD, Caligiuri MA. "The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia." Proc Natl Acad Sci. Vol. 95, no. 5. (March 1998.): 2390-2395.

Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrozek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield. "Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics." Cancer Res. Vol. 58, no. 1. (January 1998.): 55-59.

Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, Knuutila S, Marcucci G, Young DC, Held WA, Bloomfield CD, Caligiuri MA. "Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed in acute myeloid leukemia; involvement of the WIT-1 gene." Oncogene. Vol. 18, no. 20. (May 1999.): 3159-3165.

Strout MP, Marcucci G, Caligiuri MA, Bloomfield CD.. "Core binding factor (CBF) and ALL1 (MLL)-associated primary acute myeloid leukemia: biology and clinical implications.." Ann Hematol. Vol. 78, no. 6. (January 1999.): 251-.

Strout MP, Marcucci G, Caligiuri MA, Bloomfield CD. "Ann Hematol." (January 1999.): -.

Marcucci G, Caligiuri MA, Bloomfield CD. "Cancer Invest." (January 2000.): -.

Marcucci G, Caligiuri MA, Bloomfield CD.. "Molecular and clinical advances in core binding factor (CBF) primary acute myeloid leukemia: a paradigm for translational research in malignant hematology.." Cancer Invest. Vol. 18, no. 8. (January 2000.): 768-780.

Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD. "Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study." J Clin Oncol. Vol. 19, no. 9. (May 2001.): 2482-2492.

Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K, Maghraby EA, Bloomfield CD. "Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV (16) acute myeloid leukemia." Leukemia. Vol. 15, no. 7. (July 2001.): 1072-1080.

Whitman SP, Strout MP, Marcucci G, Freud AG, Culley LL, Zeleznik-le NJ, Mrozek K, Theil KS, Kees UR, Bloomfield CD, Caligiuri MA. "The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcription in B-cell acute lymphoblastic leukemia." Cancer Res. Vol. 61, no. 1. (January 2001.): 59-63.

Reuther GW, Lambert QT, Booden MA, Wennerberg K, Becknell B, Marcucci G, Sondek J, Caligiuri MA, Der CJ. "Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA." J Biol Chem. Vol. 276, no. 29. (July 2001.): 27145-27151.

Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA. "Second autologous stem cell transplant for multiply relapes Hodgkin's disease." Bone Marrow Transplant. Vol. 29, no. 9. (May 2002.): 763-767.

Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. "Leukocytoreduction for acute leukemia.." Ther Apher. Vol. 6, no. 1. (January 2002.): 15-23.

Farag SS, Elder PJ, Marcucci G, Penza S, Mrozek E, Molina A, Lin T, Avalos BR, Copelan E. "Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged >or=50 years compared to younger adults with low-risk disease.." Bone Marrow Transplant. Vol. 31, no. 2. (January 2003.): 87-93.

Marcucci,G; Perrotti,D; Caligiuri,M,A. "Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance." CLINICAL CANCER RESEARCH. Vol. 9, no. 4. (April 2003.): 1248-1252.

Porcu P, Farag S, Marcucci G, Cataland SR, Kennedy MS, Bissell M. "Ther Apher." (January 2003.): -.

Auer H, Lyianarachchi S, Newsome D, Klisovic MI, Marcucci G, Kornacker K. "Chipping away at the chips bias:RNA degradation in microarray analysis." Nat Genet. Vol. 35, no. 1. (December 2003.): 292-293.

Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK, Porcu P, Lin ZP, Farag SF, Frankel SR, Zwiebel JA, Kraut EH, Balcerzak SP, Bloomfield CD, Grever MR, Caligiuri MA. "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refactory or relapsed acute leukemia." Blood. Vol. 101, no. 2. (January 2003.): 425-432.

Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickman J, Kanakry C, Lucas DM, Reed JC, Grever MR, Byrd JC. "Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrrent with activiation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein." Blood. Vol. 102, no. 2. (July 2003.): 652-658.

Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD. "BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics:a Cancer and Leukemia Group B Study." Blood. Vol. 102, no. 5. (September 2003.): 1613-1618.

Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, Guimond M, Marcucci G. "Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines." Invest Ophthalmol Vis Sci. Vol. 44, no. 6. (June 2003.): 2390-2398.

Xiao JJ, Byrd J, Marcucci G, Grever M, Chan KK. "Indentification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood." Rapid Commun Mass Spectrom. Vol. 17, no. 8. (January 2003.): 757-766.

Becknell B, Shen T, Maghraby E, Taya S, Kaibuchi K, Caligiuri MA, Marcucci G. "Characterization of leukemia-associated Rho guanine nucleotide exchange factor (LARG) expression during murine development." Cell Tissue Res. Vol. 314, no. 3. (December 2003.): 361-366.

Marcucci G, Perrotti D, Caligiuri MA.. "Understanding the molecular basis of matinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A.N. Mohammed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.." Clin Cancer Res. Vol. 9, no. 4. (January 2003.): 1333-1337.

Marcucci G, Caligiuri MA, Bloomfield CD.. "Core Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?." Eur J Haematol. Vol. 71, no. 3. (January 2003.): 143-154.

Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. "Depsipeptide (FR901228) promotes histone acetylation, gene transcription, apoptosis and its activity is in enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells." Leukemia. Vol. 17, no. 2. (February 2003.): 350-358.

Marcucci G, Caligiuri MA, Bloomfield CD. "Eur J Haematol." (January 2003.): -.

Marcucci G, Perrotti D, Caligiuri MA. "Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A.N. Mohamed et al., The effect of imatinib mesylate on patients with Phildelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations." Clin Cancer Research. Vol. 4, no. 9. (April 2003.): 1333-1337.

Marcucci G, Mrozek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA, Carroll AJ, Koduru PR, Kolitz JE, Sterling LJ, Edwards CG, Anastasi J, Larson RA, Bloomfield CD. "Abnormal cytogenetics at date of morphologic complete remission predicts short of overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: result from cancer and leukemia group B study 8461." J Clin Oncol. Vol. 22, no. 12. (June 2004.): 2410-2418.

Perrotti D, Marcucci G, Caligiuri MA. "Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox." Journal Clinical Oncology. Vol. 22, no. 4. (February 2004.): 582-584.

Bloomfield CD, Ruppert AS, Mrozek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA. "Core binding factor acute myeloid leukemia Cancer and Leukemia Group B (CALGB) Study 8461." Ann Hematol. Vol. 83, no. Suppl 1. (January 2004.): S84-85.

Zhang L, Freitas MA, Wickham J, Parthun MR, Klisovic MI, Marcucci G, Byrd JC. "Differential expression of histone post-translation modifications in acute myeloid and chronic lymphocytic leukemai determined by high-pressure liquid chromatography and mass spectrometry." J Am Soc Mass Spectrom. Vol. 15, no. 1. (January 2004.): 77-86.

Copelan E, Hoshaw-Woodard S, Elder P, Penza S, Farag S, Marcucci G, Lin T, Ezzone S, Sholl MD, Bechtel T, Lemeshow S, Avalos B. "Therapy-related myelodysplasia and leukemia occur infrequently follow VP-16 priming and autotransplantation without total body irradiation." Bone Marrow Transplant. Vol. 34, no. 1. (July 2004.): 85-87.

Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC.. "G 3139, a BCL-2 Antisense oligonucleotide IN AML.." Ann Hematol. Vol. 83, no. Suppl 1. (January 2004.): S93-94.

Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucus D, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. "Ann Hematol." (January 2004.): -.

Bloomfield CD, Ruppert AS, Mrozek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA; Cancer and Leukemia Group B (CALGB) Study 8461. "Ann Hematol." (January 2004.): -.

Marcucci G, Mrozek K, Bloomfield CD.. "Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.." Curr Opin Hematol. Vol. 12, no. 1. (January 2005.): 68-75.

Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Stout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD, Marcucci G, Caligiuri MA. "The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy." Blood. Vol. 106, no. 1. (July 2005.): 345-352.

Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zweible JA, Larson Grever MR, Chan KK, Byrd JC. "Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia:pharmacokinetics, pharmacodynamics, and clinical activity." J Clin Oncol. Vol. 23, (January 2005.): 3404-11.

Blum W, Marcucci G.. "Targeting epigenetic changes in acute myeloid leukemia.." Clin Adv Hematol Oncol. Vol. 3, no. 11. (January 2005.): 855-865, 882.

Klisovic DD, Klisovic MI, Effron D, Liu S, Marcucci G, Katz SE. "Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for unveal melanoma." Melanoma Res. Vol. 15, no. 3. (June 2005.): 147-153.

Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C. "Global assessment of promoter methylation in a mouse model of cancer indentifies ID4 as a putative tumor-suppressor gene in human leukemia." Nat Genet. Vol. 37, no. 3. (March 2005.): 265-274.

Marcucci G, Baldus CD, Ruppert AS, Radamacher MD, Mrozek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. "Overexpression of ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study." J Clin Oncol. Vol. 23, no. 36. (December 2005.): 9234-9242.

Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO, Mayer RJ, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD. "Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8:21) differ from those of patients with inv (16): a Cancer and Leukemia Group B Study." J Clin Oncol. Vol. 23, no. 24. (August 2005.): 5705-5717.

Dai G, Chan KK, Liu S, Hoyt D, Whitman S, Klisovic M, Shen T, Caligiuri MA, Byrd J, Grever M, Marcucci G. "Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia." Clin Cancer Res. Vol. 11, no. 8. (April 2005.): 2998-3008.

Gore SD, Smith BD, Gojo I , Grever M, Kaufmann SH, Letendre L, Leonard DG, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE. "Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia." Am J Hematol. Vol. 79, no. 2. (June 2005.): 119-127.

Benson DM, O'Donnell L, Krugh D, Grady T, Blum W, Williams JD, Kennedy MS, Marcucci G. "Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis." Bone Marrow Transplant. Vol. 36, no. 12. (December 2005.): 1111-1112.

Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. "Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes." J Clin Pharmacol. Vol. 45, no. 5. (May 2005.): 597-602.

Marcucci G, Mrozek K, Bloomfield CD. Vol. 1, no. 12. (January 2005.): 68-75.

Blum W, Marcucci G. "Clin Adv Hematol Oncol." Vol. 11, no. 3. (January 2005.): 855-865.

Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK Grever MR. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia." Blood. Vol. 105, no. 3. (February 2005.): 959-967.

Neviani P, Santhanam R, Trotta R, Notari M, Blase BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D. "The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protien." Cancer Cell. Vol. 8, no. 4. (November 2005.): 355-368.

Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Chen J, Sadee W, Byrd J, Marcucci G, Chan KK. "Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protien 1." J Pharmacol Exp Ther. Vol. 313, no. 1. (April 2005.): 268-276.

Farag SS, Bowell BJ, Elder PJ, Kalaycio M, Lin T, Pohlman B, Penza S, Marcucci G, Blum W, Sobecks R, Avalos BR, Byrd JC, Copelan E. "High-dose busulfan, cyclophosphamide, and etoposide does not improve out come of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia." Bone Marrow Transplant. Vol. 35, no. 7. (April 2005.): 653-661.

Xiao JJ, Huang Y, Dai Z, Sadee W, Chen J, Liu S, Marcucci G, Byrd J, Convey JM, Wright J, Grever M, Chan KK. "Chemoresistance to depsispeptide FK228 [(E)-(1S,4S,10S,21R)-7[(Z)-ethylidene]-4,21-diisopropyl-2-oxa,12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-6-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines." J Pharmacol Exp Ther. Vol. 314, no. 1. (July 2005.): 467-475.

Dai G, Wei X, Liu Z, Liu S, Marcucci G, Chan KK. "Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reverse phase HPLC coupled with electrospray ion-trap mass sectrometry." J Chromatogr B Analyt Technol Biomed Life Sci. Vol. 825, no. 2. (October 2005.): 201-213.

Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, Yu J, Bechnell B, Li Y, Liu C, Vukosavljevic T, Whitman SP, Chang KS, Byrd JC, Perrotti D, Plass C, Marcucci G. "Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia." Cancer Res. Vol. 65, no. 3. (February 2005.): 1277-1284.

Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blase BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, Caligiuri MA. "Pro-and antiinflammatory cytokine signaling: reciprocal antagonism regulatges interferon-gamma production by human natural killer cells." Immunity. Vol. 24, no. 5. (May 2006.): 575-590.

Wei X, Dai G, Marcucci G, Liu Z, Hoyt D, Blum W, Chan KK. "A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices." Pharm Res. Vol. 23, no. 6. (January 2006.): 1251-1264.

Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreef M, Croce CM. "MicroRNA fingerprints during human megakaryocytopoiesis." Proc Natl Acad Sci. Vol. 103, no. 13. (January 2006.): 5078-5083.

Marcucci G. "Core binding factor acute myeloid leukemia.." Clin Adv Hematol Oncol. Vol. 4, no. 5. (January 2006.): 339-341.

Dorrance AM, Liu S, Yuan W, Becknell B, Amoczky KJ, Guimond M, Strout MP, Feng L, Nakamaura T, Yu L, Rush LJ, Weinstein M, Leone G, Wu L, Ferketich A, Whitman SP, Marcucci G, Caligiuri MA. "MII partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations." J Clin Invest. Vol. 116, no. 10. (October 2006.): 2707-2716.

O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, Wei X, Liu S, Marcucci G, Chan KK, Chanan-Khan A. "The combination of proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide." Clin Cancer Res. Vol. 12, no. 9. (May 2006.): 2902-2911.

Moore J, Seiter K, Kolitz J, Stock W, Giles F, Kalaycio M, Zenk D, Marcucci G. "A Phase II Study of Bcl-2 antisense (Oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse." Leuk Res. Vol. 30, no. 7. (July 2006.): 777-783.

Dai Z, Liu S, Marcucci G, Sadee W. "5-Aza-2' deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer)." Biochem Biophys Res Commun. Vol. 35, no. 2. (December 2006.): 455-461.

Wei X, Dai G, Liu Z, Cheng H, Xie Z, Marcucci G, Chan KK. "Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry." AAPS. Vol. 8, no. 4. (January 2006.): E743-755.

Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andresen S, Copelan E. "Long-term outcome of hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide and autologous stem cell transplantation." Biol Blood Marrow Transplant. Vol. 12, no. 12. (December 2006.): 1343-1349.

Blum W, Bolwell BJ, Phillips G, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobeckks RM, Pohlman B, Brown S, Elder PJ, Copelan EA. "High disease burden is associated with poor outcomes for patients with acute myeloid leukemia no in remission who undergo unrelated donor cell transplantation." Bio Blood Marrow Transplant. Vol. 12, no. 1. (January 2006.): 61-67.

Chiu SJ, Marcucci G, Lee RJ. "Efficient delivery of an antisense oligodeoxyribonucleotide formulated in folate receptor-targeted liposomes." Anticancer Res. Vol. 26, no. 2A. (March 2006.): 1049-1056.

Radmacher MD, Marcucci G, Ruppert AS, Mrozek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz CD, Caligiuri MA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. "Independent confirmation of prognostic gene-expression signature in adult acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B." Blood. Vol. 108, no. 5. (September 2006.): 1677-1683.

Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. "Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inf (16) and t(8;21): a Cancer and Leukemia group B study." J Clin Oncol. Vol. 24, no. 24. (August 2006.): 3904-3911.

Marcucci G. "Clin Adv Hematol Oncol." Vol. 5, no. 4. (May 2006.): 339-341.

Liu Z, Marcucci G, Byrd JC, Grever M, Xiao J, Chan KK. "Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method." Rapid Commun Mass Spectrom. Vol. 20, no. 7. (April 2006.): 1117-1126.

Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ. "Efficient delivery of a Bcl-2 specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes." J Control Release. Vol. 112, no. 2. (May 2006.): 199-207.

Notari M, Neviani P, Santhanam R, Blase BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G, Perrotti D. "A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation." Blood. Vol. 107, no. 6. (March 2006.): 2507-2516.

Baldus CD, Mrózek K, Marcucci G, and Bloomfield CD.. "Clinical Outcome of De Novo Acute Myeloid Leukemia Patients with Normal Cytogenetics is Affected by Molecular Genetic Alterations: A Concise Review.." Br J Haematol. Vol. 137, no. 5. (January 2007.): 387-400.

Lu Y, Wu J, Wu J, Gonit M, Yang X, Lee A, Xiang G, Li H, Liu S, Marcucci G, Ratnam M, Lee RJ. "Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells." Mol Pharm. Vol. 4, no. 5. (September 2007.): 707-712.

Baldus CD, Mrozek K, Marcucci G, Bloomfield CD. "Br J Haematol." Vol. 5, no. 137. (June 2007.): 387-400.

Neviani P, Santhanam R, Oaks, JJ, Eiring AM, Notari M, Blaser BW, Liu, S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D. "FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia." J Clin Invest. Vol. 117, no. 9. (September 2007.): 2408-2421.

Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebener K, Croce CM. "MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B." Proc Natl Acad Sci USA. Vol. 104, no. 40. (October 2007.): 15805-15810.

Zhang L, Su X, Liu S, Knapp AR, Parthum MR, Marcucci G, Freitas Ma. "Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsidpeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry." J Proteome Res. Vol. 6, no. 1. (January 2007.): 81-88.

Su X, Zhang, Lucus DM, Davis ME, Knapp AR, Green-Church KB, Marcucci G, Parthun MR, Byrd JC, Freitas MA. "Histone H4 acetylation dynamics determined stable isotope labeling with amino acids in cell structure and mass spectrometry." Anal Biochem. Vol. 363, no. 1. (April 2007.): 22-34.

Whitman SP, Ruppert AS, Marcucci G, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, larson RA, Caligiuri MA, Bloomfield CD. "Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL patrial tandem duplication: a Cancer and Leukemia Group B study." Blood. Vol. 109, no. 12. (June 2007.): 5164-5167.

Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, Huynh L, Pang J, Neviani P, Liu Z, Blum W, Chan KK, Perrotti D, Marcucci G. "Targeting AML 1/ETO-histone deacetylase respessor complex: a novel valproic acid-mediated gene expession and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells." J Pharmacol Exp Ther. Vol. 321, no. 3. (June 2007.): 953-960.

Yu J, Wei M, Boyd Z, Lehmann EB, Trotta R, Mao H, Liu S, Becknell B, Jaung MS, Jarjoura D, Marcucci G, Wu LC, Caligiuri MA. "Transcriptional control of human T-BET expression: the role of Sp1." Eur J Immunol. Vol. 37, no. 9. (September 2007.): 2549-2561.

Su X, Jacob NK, Amunugama R, Lucas DM, Knapp AR, Ren C, Davis ME, Marcucci G, Parthun MR, Byrd JC, Fishel R, Freitas MA. "Liquid chromatography mass spectrometry profiling of histones." J Chromatogr B Analyt Technol Biomed Life Sci. Vol. 850, no. 1-2. (January 2007.): 440-454.

Shah MH, Villalona-Calero MA, Marcucci G, Byrd JC, Grever MR.. "HDAC Inhibitors and Cardiac Safety.." Clin Cancer Res. Vol. 13, no. 3. (January 2007.): 1068-.

Cheng H, Liu Z, Blum W, Byrd JC, Klisovic R, Grever MR, Marcucci G, Chan KK. "Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS." J Chromatogr B Analyt Technol Biomed Life Sci. Vol. 850, no. 1-2. (May 2007.): 206-212.

Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrozek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B study. "High expression of levels of the ETS-related gene, ERG predict adverse outcome and improve molecular risk-based classification of cytogenetically normal myeloid leukemia: a Cancer and Leukemia Group B Study." J Clin Oncol. Vol. 25, no. 22. (August 2007.): 3337-3343.

Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, Klisovic R, Byrd J, Chan KK, Marcucci G. "Characterization of in vitro and in vivo hypomethlating effects of decitabine in acute myeloid leukemia by rapid, specific and sensitive LC-MS/MS method." Nucleic Acids Res. Vol. 35, no. 5. (January 2007.): e31-.

Mrózek K, Marcucci G, Ruppert AS, Baldus CD, Kolitz JE, Larson RA, Bloomfield CD.. "Molecular heterogeneity and its prognostic significance in acute myeloid leukemia (AML) with normal cytogenetics.." Ann Hematol. Vol. 85, no. Suppl 13. (January 2007.): 114-117.

Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. "Blood." Vol. 2, no. 109. (January 2007.): 431-448.

Ali NA, O'Brien JM Jr, Blum W, Byrd JC, Klisovic RB, Marcucci G, Phillips G, Marsh CB Lemeshow S, Grever MR. "Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality." Cancer. Vol. 110, no. 1. (July 2007.): 96-102.

Blum W, Klisovic RB, Hackason B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G. "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid Leukemia." J Clin Oncol. Vol. 25, no. 25. (September 2007.): 3884-3891.

Mrózek K, Paschka P, Marcucci G, Whitman SP, Bloomfield CD.. "Biology, cytogenetics and molecular studies in acute myeloid leukemia.." Leuk Res. Vol. 31, no. Suppl 2. (September 2007.): S3-7.

Ren,Chen; Liu,Shujun; Ghoshal,Kalpana; Hsu,Pang-Hung; Jacob,Samson,T; Marcucci,Guido; Freitas,Michael,A. "Simultaneous metabolic labeling of cells with multiple amino acids: Localization and dynamics of histone acetylation and methylation." PROTEOMICS CLINICAL APPLICATIONS. Vol. 1, no. 1. (January 2007.): 130-142.

Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD.. "Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?." Blood. Vol. 109, no. 2. (January 2007.): 431-448.

Mrózek K, Marcucci G, Paschka P, Bloomfield CD.. "Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.." Curr Opin Oncol. Vol. 20, no. 6. (January 2008.): 711-718.

Paoluzzi L, Gonen M, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O'Conner OA. "Targeting Bcl-2 family members with BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cells lymphoma." Blood. Vol. 111, no. 11. (June 2008.): 5350-5358.

Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreef M, Croce CM. "MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia." Blood. Vol. 111, no. 9. (March 2008.): 3183-3189.

Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu C-G, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD.. "Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 26, no. 31. (January 2008.): 5078-87.

Wei X, Dai G, Liu Z, Cheng H, Xie Z, Klisovic R, Marcucci G, Chan KK.. "Enzyme Kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase." Drug Metab Dispos. Vol. 11, no. 36. (November 2008.): 2227-33.

Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L Pang J, Zweibel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. "Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia." Clinical Cancer Res. Vol. 14, no. 12. (June 2008.): 3889-3895.

Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. "Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia group B study." Journal Clinical Oncology. Vol. 28, no. 26. (October 2008.): 4595-602.

Whitman SP, Ruppert AS, Radamacher MD, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. "FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications." Blood. Vol. 111, no. 3. (February 2008.): 1552-1559.

Liu S, Liu Z, Xie Z, Pang J, Yu J, Lhmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G. "Bortezomib induces DNA hypomethlation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia." Blood. Vol. 111, no. 4. (February 2008.): 2364-2373.

Fehniger TA, Byrd Jc, Marcucci G, Abboud CN, Defauver C, Payton JE, Vij R, Blum, W. "Single agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13." Blood. Vol. 113, no. 5. (September 2008.): 1002-1005.

Plass C, Oakes C, Blum W, Marcucci G.. "Epigenetics in acute myeloid leukemia.." Semin Oncol. Vol. 35, no. 4. (January 2008.): 378-387.

Blum W, Marcucci G.. "New approaches in acute myeloid leukemia.." Best Pract Res Clin Haematol. Vol. 21, no. 2. (January 2008.): 29-41.

Klisovic RB, Stock W, Cataland S, Klisovic MI, Liu S, Blum W, Green M, Odenike O, Godley L, Burgt JV, Van Laar E, Cullen M, Macleod AR, Besterman JM, Reid GK, Byrd JC, Marcucci. "A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia." Clinical Cancer Res. Vol. 14, no. 8. (April 2008.): 2444-2449.

Plass C, Oaks C, Blum W, Marcucci G. "Epigenetics in acute myeloid leukemia." Vol. 4, no. 35. (August 2008.): 378-87.

Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, Caligiuri MA, Leone GW, Perrotti D. "Identification of novel posttranscriptional targets of the BCR/ABL oncoprotien by ribonomics:requirements of E2F3 for BCR/ABL Leukemogenesis." Blood. Vol. 111, no. 2. (January 2008.): 816-828.

Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD, Lubbert M, Marcucci G, Bloomfield CD, Plass C. "Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia." Cancer Res. Vol. 68, no. 9. (May 2008.): 3142-3151.

Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, LozanskiG, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. "Lenalidomide down-regulates the CD20 antigen and antangonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells." Blood. Vol. 112, no. 13. (September 2008.): 5180-5189.

Marcucci G, Radamacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Cloomfield CD. "MicroRNA expression in cytogenetically normal acute myeloid leukemia." New England Journal of Medicine. Vol. 358, no. 18. (May 2008.): 1919-1928.

Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC. "A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapy agents." Clin Cancer Res. Vol. 14, no. 2. (January 2008.): 569-578.

Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA. "DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication." Blood. Vol. 5, no. 112. (September 2008.): 2013-2016.

O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stone RM, Tallman MS, Wang E, White FL.. "Acute myeloid leukemia.." . J Natl Compr Canc Netw. Vol. 6, no. 10. (January 2008.): 962-993.

Dorrance AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M, Yuan W, Chang D, Whitman SP, Marcucci G, Caligiuri MA.. "The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.." Blood. Vol. 112, no. 6. (January 2008.): 2508-11.

Langer C, Radamacher MD, Ruppert AS, Whitman SP, Paschka P, Mrozek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD: Cancer and Leukemia Group B. "High BAACL expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B study." Blood. Vol. 111, no. 11. (June 2008.): 5371-9.

Blum W, Marcucci G. Vol. 1, no. 21. (March 2008.): 29-41.

Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul Dr, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS. "Prevention and treatment of cancer-related infections." J Natl Compr Canc Netw. Vol. 6, no. 2. (February 2008.): 122-174.

Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ. "Novel liposomal formulation of flavopiridol." Int J Pharm. Vol. 365, no. 1-2. (August 2008.): 170-174.

Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA; for the Cancer and Leukemia Group B. "A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia CALGB Study 19804." Cancer Chemother Pharmacol. Vol. 63, no. 5. (August 2008.): 859-864.

Marcucci G, Maharry K, Radamacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD. "Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study." Journal of Clinical Oncology. Vol. 26, no. 31. (November 2008.): 5078-5087.

Neubauer A, Maharry K, Mrózek K, Thiede G, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD. "Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol. 26, no. 28. (January 2008.): 4603-4609.

Bloomfield CD, Marcucci G, Dohner K, Dohner H. "Acute Myeloid Leukemia Induction." Semin Oncol. Vol. 4, no. 35. (August 2008.): 324-325.

Mrozek K, Marcucci G, Paschka P, Bloomfield CD. Curr Opin Oncol. Vol. 6, no. 20. (November 2008.): 711-8.

Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM. "Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation." Biol Blood Marro Transplant. Vol. 14, no. 7. (July 2008.): 783-789.

Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, Li PK, Lin J, Fuchs JR, Marcucci G, Li C, Chan KK.. "Curcumin is a potent DNA hypomethylation agent." Bioorg Med Chem Lett. Vol. 19, no. 3. (January 2008.): 706-709.

Marcucci,Guido; Radmacher,Michael,D; Bloomfield,Clara,D. "MicroRNA in acute myeloid leukemia - Reply." NEW ENGLAND JOURNAL OF MEDICINE. Vol. 359, no. 6. (August 2008.): 653-654.

Whitman,Susan,P; Marcucci,Guido; Ruppert,Amy,S; Mrozek,Krzysztof; Bloomfield,Clara,D. "Conflicting data on the prognostic significance of FLT3-TKD mutations in cytogenetically normal acute myelold leukemia (CN-AML) might be related to many factors, including techniques used to detect FLT3-TKD, differences in patient populations studied, and treatment regimens - Response." BLOOD. Vol. 112, no. 2. (July 2008.): 445-445.

Mehta,Rajendra,H; Rao,Sunil,V; Ohman,E,Magnus; Bates,Eric,R; Marcucci,Gretchen; Zhang,Min; Pieper,Karen,S; Armstrong,Paul,W; White,Harvey,D; de Werf,Frans,Van; Califf,Robert,M; Granger,Christopher,B. "Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb." EUROPEAN HEART JOURNAL. Vol. 29, no. 7. (April 2008.): 880-887.

Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radamacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Buchner T, Wormann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C; CALGB;. "An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid Leukemia." Blood. Vol. 112, no. 10. (November 2008.): 4193-4201.

Chen SS, Raval A, Johnson AJ, Hertlein E, Liu TH, Jin VX, Sherman MH, Liu SJ, Dawson DW, Williams KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, Pekarsky Y, Davuluri R, Croce CM, Guttridge DC, Teitell MA, Byrd JC, Plass C. "Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.." Proc Natl Acad Sci U S A. Vol. 106, no. 32. (August 2009.): 13433-13448.

Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, Chen P, Aimiuwu J, Pang J, Bhasin D, Neviani P, Fuchs JR, Plass C, Li PK, Li C, Huang TH, Wu LC, Rush L, Wang H, Perrotti D, Marcucci G, Chan KK.. "Modulation of DNA methylation by a sesquiterpene lactone parthenolide.." J Pharmacol Exp Ther. Vol. 329, no. 2. (May 2009.): 505-514.

Garzon R, Heaphy CCE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M and Croce CM.. "MicroRNA 29b functions in acute myeloid leukemia.." Blood. (July 2009.): -.

Liu Z, Wu J, Xie Z, Liu S, Fan-Havard P, Huang TH, Plass C, Marcucci G, Chan KK.. "Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry.." Anal Biochem. Vol. 391, no. 2. (August 2009.): 106-113.

Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrózek K, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD.. "Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.." J Clin Oncol. Vol. 27, no. 19. (July 2009.): 3198-3204.

Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM.. "Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.." Biol Blood Marrow Transplant. Vol. 15, no. 11. (November 2009.): 1422-1430.

Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreef M, Bloomfield CD, Byrd JC, Chan K, Wu L-C, Croce CM, and Marcucci G.. "MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1." Blood. Vol. 113, no. 25. (June 2009.): 6411-6418.

Garzon R, Heaphy CCE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M and Croce CM. "MicroRNA 29b functions in acute myeloid leukemia." Blood. Vol. 114, no. 26. (December 2009.): 5331-5341.

Su X, Lucas DM, Zhang L, Xu H, Zabrouskov V, Davis ME, Knapp AR, Young DC, Payne PR, Parthun MR, Marcucci G, Grever MR, Byrd JC, Freitas MA.. "Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.." Proteomics. Vol. 9, no. 5. (March 2009.): 1197-1206.

Mrózek K, Radmacher MD, Bloomfield CD, Marcucci G. "Molecular signatures in acute myeloid leukemia.." Curr Opin Hematol. Vol. 16, no. 2. (March 2009.): 64-69.

Zhang X, Koh CG, Yu B, Liu S, Piao L, Marcucci G, Lee RJ, Lee LJ.. "Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.." Pharm Res. Vol. 26, no. 6. (January 2009.): 1516-1524.

Yang X, Koh CG, Liu S, Pan X, Santhanam R, Yu B, Peng Y, Pang J, Golan S, Talmon Y, Jin Y, Muthusamy N, Byrd JC, Chan KK, Lee LJ, Marcucci G, Lee RJ.. "Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2.." Mol Pharm. Vol. 6, no. 1. (January 2009.): 221-230.

Yu J, Wei M, Mao H, Zhang J, Hughes T, Mitsui T, Park I, Hwang C, Liu S, Marcucci G, Trotta R, Benson Jr. DM, and Caligiuri MA. "CD94 Defines Phenotypically and Functionally Distinct Mouse NK Cell Subsets.." J Immunol. Vol. 183, (February 2009.): 4968-4974.

Yu J, Ershler M, Yu L, Wei M, Hackanson B, Yokohama A, Mitsui T, Liu C, Mao H, Liu S, Liu Z, Trotta R, Liu CG, Liu X, Huang K, Visser J, Marcucci G, Plass C, Belyavsky AV, Caligiuri MA.. "TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.." Blood. Vol. 113, no. 22. (May 2009.): 5558-5567.

Marcucci G. "Molecular markers in acute myeloid leukemia." Clin Adv Hematol Oncol. Vol. 7, no. 7. (January 2009.): 448-451.

Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM.. "Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.." Biol Blood Marrow Transplant. Vol. 15, no. 5. (January 2009.): 547-553.

Chen P, Liu Z, Liu S, Xie Z, Aimiuwu J, Pang J, Klisovic R, Blum W, Grever MR, Marcucci G, Chan KK.. "A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.." Pharm Res. Vol. 26, no. 6. (June 2009.): 1504-1515.

Weecharangsan W, Yu B, Zheng Y, Liu S, Pang J, Lee LJ, Marcucci G, Lee R. "Efficient delivery of antisense oligodeoxyribonucleotide G3139 by human serum albumin-coated liposomes." Mol Pharm. Vol. 6, no. 6. (November 2009.): 1848-1855.

Marcucci,Guido; Radmacher,Michael,D; Mrózek,Krzysztof; Bloomfield,Clara,D. "MicroRNA expression in acute myeloid leukemia.." Current hematologic malignancy reports. Vol. 4, no. 2. (April 2009.): 83-88.

Marcucci,Guido; Maharry,Kati; Mrozek,Krzysztof; Bloomfield,Clara,D. "Role of CEBPA in Normal Karyotype Acute Myeloid Leukemia Reply." JOURNAL OF CLINICAL ONCOLOGY. Vol. 27, no. 12. (April 2009.): 2106-2106.

Marcucci G, Mrózek K, Radmacher MD, Bloomfield CD, Croce CM. "MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.." Best Pract Res Clin Haematol. Vol. 22, no. 2. (June 2009.): 448-451.

Khandanpour C, Thiede C, Valk PJ, Sharif-Askari E, Nückel H, Lohmann D, Horsthemke B, Siffert W, Neubauer A, Grzeschik KH, Bloomfield CD, Marcucci G, Maharry K, Slovak ML, van der Reijden BA, Jansen JH, Schackert HK, Afshar K, Schnittger S, Peeters JK, Kroschinsky F, Ehninger G, Lowenberg B, Dührsen U, Möröy T.. "A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.." Blood. Vol. 115, no. 12. (March 2010.): 2462-2472.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD. "Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study." J Clinical Onc. Vol. 28, no. 4. (February 2010.): 596-604.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Paschka P, Holland KB, Schwind S, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Bloomfield CD.. "Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.." Blood. Vol. 116, no. 5. (August 2010.): 788-792.

Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, and Byrd JC. "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation." Br J Haematol. Vol. 150, no. 2. (July 2010.): 189-195.

Wang L, Harshman SW, Liu S, Ren C, Xu H, Sallans L, Grever M, Byrd JC, Marcucci G, Freitas MA.. "Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.." Proteomics. Vol. 10, no. 23. (December 2010.): 4281-4292.

Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, and Larson RA.. "P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.." Blood First Edition Paper. Vol. 116, no. 9. (September 2010.): 1413-1421.

Jin Y, Liu S, Yu B, Godan S, Koh C-G, Yang J, Huynh L, Yang X, Pang J, Muthusamy N, Chan K, Byrd JC, Talmon Y, Lee LJ, Lee R, and Marcucci G.. "Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide –Based Therapeutic Strategy in Acute Myeloid Leukemia.." Mol. Pharmaceutics.. Vol. 7, no. 1. (February 2010.): 196-206.

Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman, SP Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, and Bloomfield CD. "IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study." J Clin Oncol. Vol. 28, no. 14. (May 2010.): 2348-2355.

Whitman SP, Maharry K, Radmacher MD, Becker H, Mrózek K, Margeson D, Holland KB, Wu YZ, Schwind S, Metzeler KH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Moore JO, Stone RM, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.. "FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.." Blood. Vol. 116, no. 18. (August 2010.): 3622-3626.

Garzon R, Marcucci G, Croce C.. "Targeting microRNAs in cancer: Rationale, strategies and challenges.." Nat Rev Drug Discov. Vol. 9, no. 10. (October 2010.): 775-789.

Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, and Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." PNAS. Vol. 107, no. 16. (April 2010.): 7473-7478.

Eiring AM¸ Neviani P, Garton C, Spizzo R, Liu S, Oaks JJ, Hickey C, Santhanam R, Harb JG, Chandler JD, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D.. "miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts.." Cell. Vol. 140, no. 5. (March 2010.): 652-665.

Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd JC.. "Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias.." J Clin Oncol. Vol. 28, no. 33. (October 2010.): 4919-4925.

Chan KK, Liu Z, Xie Z, Chiu M, Wang H, Chen P, Dunkerson S, Chiu M, Liu S, Triantafillou G, Garzon R, Croce CM, Byrd JC, Muthusamy N, Marcucci G.. "A Novel Ultrasensitive Hybridization-Based ELISA Method for 2-Methoxyphosphorothiolate MicroRNAs and Its In vitro and In vivo Application.." AAPS J. Vol. 12, no. 4. (August 2010.): 556-568.

Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu P.. "New targets of therapy in T-cell lymphomas.." Curr Drug Targets. Vol. 11, no. 4. (April 2010.): 482-493.

Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson A, Schaaf LJ, Byrd JC, Marcucci G, and Grever MR. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias." Haematologica,. Vol. 95, no. 7. (May 2010.): 1098-1105.

Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD.. "BAALC and ERG expression levels are associated with outcome and distinct gene- and microRNA-expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.." Blood. Vol. 116, no. 25. (September 2010.): 5660-5669.

Chen P, Aimiuwu J, Xie Z, Wei X, Liu S, Klisovic R, Marcucci G, Chan KK.. "Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells.." AAPS. Vol. 13, no. 1. (December 2010.): 131-140.

Weecharabgsan W, Yu B, Liu S, Pang J, Lee, LJ, Marcucci G, Lee RJ. "Disulfide-linked Liposomes: Effective Delivery Vehicle for Bcl-2 Antisense Oligodeoxyribonucleotide G3139." Anticancer Research. Vol. 30, no. 1. (January 2010.): 31-37.

Stone RM, Moser B, Sanford B, Schulman P, Kolitz JE, Allen S, Stock W, Galinsky I, Vij R, Marcucci G, Hurd D, Larson RA. "High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.." Leuk Res. Vol. 35, no. 3. (August 2010.): 329-333.

Klein RD, Marcucci G. "Familial Acute Myeloid Leukemia (AML) with Mutated CEBPA." GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle. (October 2010.): -.

Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD.. "The prognostic and functional role of microRNAs in acute myeloid leukemia." Blood First Edition Paper. Vol. 117, no. 4. (November 2010.): 1121-1129.

Yu J, Mao HC, Wei M, Hughes T, Zhang J, Park I, Liu S, McClory S, Marcucci G, Trotta R, and Caligiuri MA.. "CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK cell subsets.." Blood. Vol. 115, no. 2. (January 2010.): 274-281.

Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD.. "Prognostic Significance of Expression of a Single MicroRNA, miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study.." J Clin Oncol. Vol. 28, no. 36. (December 2010.): 5257-5264.

Li H, Lu Y, Piao L, Wu J, Liu S, Marcucci G, Ratnam M, Lee RJ. "Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid.." Int J Pharm. Vol. 402, no. 1-2. (December 2010.): 57-63.

Koh CG, Zhang X, Liu S, Golan S, Yu B, Yang X, Guan J, Yan J, Talmon Y, Muthasamy R, Chan KK, Bryd J, Lee RJ, Marcucci G, Lee LJ.. "Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing." J Control Release. Vol. 141, no. 1. (January 2010.): 62-69.

Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G.. "Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.." Cancer Cell. Vol. 17, no. 4. (April 2010.): 333-347.

Liu S, Madiai F, Hackshaw KV, Allen CE, Carl J, Huschart E, Karanfilov C, Litsky A, Hickey CJ, Marcucci G, Huja S, Agarwal S, Yu J, Caligiuri MA, Wu LC.. "The Large Zinc Finger Protein ZAS3 Is a Critical Modulator of Osteoclastogenesis. PLoS One.." PLoS One. Vol. 6, no. 3. (March 2011.): e17161-.

Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, Zhang J, Mishra A, Alvarez-Breckenridge C, Liu X, Liu S, Yokohama A, Trotta R, Marcucci G, Benson DM Jr, Loughran TP Jr, Tridandapani S, Caligiuri MA.. "NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.." J Clin Invest. Vol. 121, no. 4. (March 2011.): 1456-1470.

Schwind,Sebastian; Marcucci,Guido; Kohlschmidt,Jessica; Radmacher,Michael,D; Mrozek,Krzysztof; Maharry,Kati; Becker,Heiko; Metzeler,Klaus,H; Whitman,Susan,P; Wu,Yue-Zhong; Powell,Bayard,L; Baer,Maria,R; Kolitz,Jonathan,E; Carroll,Andrew,J; Larson,Richard,A; Caligiuri,Michael,A; Bloomfield,Clara,D. "Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia." BLOOD. Vol. 118, no. 15. (October 2011.): 4188-4198.

Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G, Croce CM, Garzon R.. "Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling.." Cancer. Vol. 117, no. 20. (March 2011.): 4696-4706.

Salas A, Ponnusamy S, Senkal CE, Meyers M, Selvam SP, Saddoughi SA, Apohan E, Sentelle RD, Smith C, Gault CR, Obeid LM, El-Shewy HM, Oaks J, Santhanam R, Marcucci G, Baran Y, Mahajan S, Fernandes D, Stuart R, Perrotti D, Ogretmen B.. "Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.." Blood. Vol. 117, no. 22. (April 2011.): 5941-5952.

Metzeler,Klaus,H; Becker,Heiko; Maharry,Kati; Radmacher,Michael,D; Kohlschmidt,Jessica; Mrozek,Krzysztof; Nicolet,Deedra; Whitman,Susan,P; Wu,Yue-Zhong; Schwind,Sebastian; Powell,Bayard,L; Carter,Thomas,H; Wetzler,Meir; Moore,Joseph,O; Kolitz,Jonathan,E; Baer,Maria,R; Carroll,Andrew,J; Larson,Richard,A; Caligiuri,Michael,A; Marcucci,Guido; Bloomfield,Clara,D. "ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category." BLOOD. Vol. 118, no. 26. (December 2011.): 6920-6929.

Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield CD.. "The prognostic and functional role of microRNAs in acute myeloid leukemia.." Blood. Vol. 117, no. 4. (January 2011.): 1121-1129.

Marcucci G, Haferlach T, Döhner H.. "Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications.." j Clin Oncol. Vol. 29, no. 5. (January 2011.): 475-486.

Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.. "TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study.." J Clin Oncol. Vol. 29, no. 10. (February 2011.): 1373-1381.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES.. "Acute myeloid leukemia.." J Natl Compr Canc Netw. Vol. 9, no. 3. (March 2011.): 280-317.

Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, Dipersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ; on behalf of the Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B. "Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60-70 Years with Acute Myelogenous Leukemia in First Remission." Biol Blood Marrow Transplant. Vol. 17, no. 12. (June 2011.): 1796-1803.

Wu LC, Pfeiffer DR, Calhoon EA, Madiai F, Marcucci G, Liu S, Jurkowitz MS.. "Purification, identification, and cloning of lysoplasmalogenase, the enzyme that catalyzes hydrolysis of the vinyl ether bond of lysoplasmalogen.." J Biol Chem. Vol. 286, no. 28. (April 2011.): 24916-24930.

Saradhi UV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas DM, Grever MR, Phelps MA, Chan KK.. "Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry.." AAPS. Vol. 13, no. 3. (April 2011.): 347-356.

Becker H, Maharry K, Radmacher M, Mrozek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu YZ, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA, Larson RA, Marcucci G, Bloomfield CD. "Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study." Haematologica. Vol. 96, no. 10. (June 2011.): 1488-1495.

Walker A, Marcucci G.. "Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse.." Haematologica. (May 2011.): -.

Kuehnl,Andrea; Kaiser,Martin; Neumann,Martin; Fransecky,Lars; Heesch,Sandra; Radmacher,Michael; Marcucci,Guido; Bloomfield,Clara,D; Hofmann,Wolf-Karsten; Thiel,Eckhard; Baldus,Claudia,D. "High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia." LEUKEMIA RESEARCH. Vol. 35, no. 12. (December 2011.): 1585-1590.

Mendler,Jason,H; Maharry,Kati; Radmacher,Michael,D; Mrozek,Krzysztof; Becker,Heiko; Metzeler,Klaus,H; Schwind,Sebastian; Whitman,Susan,P; Khalife,Jihane; Kohlschmidt,Jessica; Nicolet,Deedra; Powell,Bayard,L; Carter,Thomas,H; Wetzler,Meir; Moore,Joseph,O; Kolitz,Jonathan,E; Baer,Maria,R; Carroll,Andrew,J; Larson,Richard,A; Caligiuri,Michael,A; Marcucci,Guido; Bloomfield,Clara,D. "RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures." JOURNAL OF CLINICAL ONCOLOGY. Vol. 30, no. 25. (September 2012.): 3109-3118.

Marcucci,Guido; Metzeler,Klaus,H; Schwind,Sebastian; Becker,Heiko; Maharry,Kati; Mrozek,Krzysztof; Radmacher,Michael,D; Kohlschmidt,Jessica; Nicolet,Deedra; Whitman,Susan,P; Wu,Yue-Zhong; Powell,Bayard,L; Carter,Thomas,H; Kolitz,Jonathan,E; Wetzler,Meir; Carroll,Andrew,J; Baer,Maria,R; Moore,Joseph,O; Caligiuri,Michael,A; Larson,Richard,A; Bloomfield,Clara,D. "Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia." JOURNAL OF CLINICAL ONCOLOGY. Vol. 30, no. 7. (March 2012.): 742-750.

Shlush,Liran,I; Chapal-Ilani,Noa; Adar,Rivka; Pery,Neta; Maruvka,Yosef; Spiro,Adam; Shouval,Roni; Rowe,Jacob,M; Tzukerman,Maty; Bercovich,Dani; Izraeli,Shai; Marcucci,Guido; Bloomfield,Clara,D; Zuckerman,Tsila; Skorecki,Karl; Shapiro,Ehud. "Cell lineage analysis of acute leukemia relapse uncovers the role of replication-rate heterogeneity and microsatellite instability." BLOOD. Vol. 120, no. 3. (July 2012.): 603-612.

Blum,William; Schwind,Sebastian; Tarighat,Somayeh,S; Geyer,Susan; Eisfeld,Ann-Kathrin; Whitman,Susan; Walker,Alison; Klisovic,Rebecca; Byrd,John,C; Santhanam,Ramasamy; Wang,Hongyan; Curfman,John,P; Devine,Steven,M; Jacob,Samson; Garr,Celia; Kefauver,Cheryl; Perrotti,Danilo; Chan,Kenneth,K; Bloomfield,Clara,D; Caligiuri,Michael,A; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.

Ranganathan,Parvathi; Heaphy,Catherine,EA; Costinean,Stefan; Stauffer,Nicole; Na,Caroline; Hamadani,Mehdi; Santhanam,Ramasamy; Mao,Charlene; Taylor,Patricia,A; Sandhu,Sukhinder; He,Gang; Shana'ah,Arwa; Nuovo,Gerard,J; Lagana,Alessandro; Cascione,Luciano; Obad,Susanna; Broom,Oliver; Kauppinen,Sakari; Byrd,John,C; Caligiuri,Michael; Perrotti,Danilo; Hadley,Gregg,A; Marcucci,Guido; Devine,Steven,M; Blazar,Bruce,R; Croce,Carlo,M; Garzon,Ramiro. "Regulation of acute graft-versus-host disease by microRNA-155." BLOOD. Vol. 119, no. 20. (May 2012.): 4786-4797.

Mrózek,Krzysztof; Marcucci,Guido; Nicolet,Deedra; Maharry,Kati,S; Becker,Heiko; Whitman,Susan,P; Metzeler,Klaus,H; Schwind,Sebastian; Wu,Yue-Zhong; Kohlschmidt,Jessica; Pettenati,Mark,J; Heerema,Nyla,A; Block,Annemarie,W; Patil,Shivanand,R; Baer,Maria,R; Kolitz,Jonathan,E; Moore,Joseph,O; Carroll,Andrew,J; Stone,Richard,M; Larson,Richard,A; Bloomfield,Clara,D. "Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia.." Journal of clinical oncology. Vol. 30, no. 36. (December 2012.): 4515-4523.

Chou,Fu-Sheng; Griesinger,Andrea; Wunderlich,Mark; Lin,Shan; Link,Kevin,A; Shrestha,Mahesh; Goyama,Susumu; Mizukawa,Benjamin; Shen,Shuhong; Marcucci,Guido; Mulloy,James,C. "The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO." BLOOD. Vol. 120, no. 4. (July 2012.): 709-719.

Eisfeld,Ann-Kathrin; Marcucci,Guido; Maharry,Kati; Schwind,Sebastian; Radmacher,Michael,D; Nicolet,Deedra; Becker,Heiko; Mrozek,Krzysztof; Whitman,Susan,P; Metzeler,Klaus,H; Mendler,Jason,H; Wu,Yue-Zhong; Liyanarachchi,Sandya; Patel,Ravi; Baer,Maria,R; Powell,Bayard,L; Carter,Thomas,H; Moore,Joseph,O; Kolitz,Jonathan,E; Wetzler,Meir; Caligiuri,Michael,A; Larson,Richard,A; Tanner,Stephan,M; De la Chapelle,Albert; Bloomfield,Clara,D. "miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia." BLOOD. Vol. 120, no. 2. (July 2012.): 249-258.

Aimiuwu,Josephine; Wang,Hongyan; Chen,Ping; Xie,Zhiliang; Wang,Jiang; Liu,Shujun; Klisovic,Rebecca; Mims,Alice; Blum,William; Marcucci,Guido; Chan,Kenneth,K. "RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia." BLOOD. Vol. 119, no. 22. (May 2012.): 5229-5238.

Metzeler,K,H; Walker,A; Geyer,S; Garzon,R; Klisovic,R,B; Bloomfield,C,D; Blum,W; Marcucci,G. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." LEUKEMIA. Vol. 26, no. 5. (May 2012.): 1106-1107.

Mishra,Anjali; Liu,Shujun; Sams,Gregory,H; Curphey,Douglas,P; Santhanam,Ramasamy; Rush,Laura,J; Schaefer,Deanna; Falkenberg,Lauren,G; Sullivan,Laura; Jaroncyk,Laura; Yang,Xiaojuan; Fisk,Harold; Wu,Lai-Chu; Hickey,Christopher; Chandler,Jason,C; Wu,Yue-Zhong; Heerema,Nyla,A; Chan,Kenneth,K; Perrotti,Danilo; Zhang,Jianying; Porcu,Pierluigi; Racke,Frederick,K; Garzon,Ramiro; Lee,Robert,J; Marcucci,Guido; Caligiuri,Michael,A. "Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation." CANCER CELL. Vol. 22, no. 5. (November 2012.): 645-655.

Li,Zejuan; Huang,Hao; Li,Yuanyuan; Jiang,Xi; Chen,Ping; Arnovitz,Stephen; Radmacher,Michael,D; Maharry,Kati; Elkahloun,Abdel; Yang,Xinan; He,Chunjiang; He,Miao; Zhang,Zhiyu; Dohner,Konstanze; Neilly,Mary,Beth; Price,Colles; Lussier,Yves,A; Zhang,Yanming; Larson,Richard,A; Le Beau,Michelle,M; Caligiuri,Michael,A; Bullinger,Lars; Valk,Peter,JM; Delwel,Ruud; Lowenberg,Bob; Liu,Paul,P; Marcucci,Guido; Bloomfield,Clara,D; Rowley,Janet,D; Chen,Jianjun. "Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML." BLOOD. Vol. 119, no. 10. (March 2012.): 2314-2324.

Koleva,Rositsa,I; Ficarro,Scott,B; Radomska,Hanna,S; Carrasco-Alfonso,Marlene,J; Alberta,John,A; Webber,James,T; Luckey,C,John; Marcucci,Guido; Tenen,Daniel,G; Marto,Jarrod,A. "C/EBP alpha and DEK coordinately regulate myeloid differentiation." BLOOD. Vol. 119, no. 21. (May 2012.): 4878-4888.

Claus,Rainer; Lucas,David,M; Stilgenbauer,Stephan; Ruppert,Amy,S; Yu,Lianbo; Zucknick,Manuela; Mertens,Daniel; Buehler,Andreas; Oakes,Christopher,C; Larson,Richard,A; Kay,Neil,E; Jelinek,Diane,F; Kipps,Thomas,J; Rassenti,Laura,Z; Gribben,John,G; Doehner,Hartmut; Heerema,Nyla,A; Marcucci,Guido; Plass,Christoph; Byrd,John,C. "Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia." JOURNAL OF CLINICAL ONCOLOGY. Vol. 30, no. 20. (July 2012.): 2483-2491.

Wang,Hongyan; Chiu,Ming; Xie,Zhiliang; Chiu,Michael; Liu,Zhongfa; Chen,Ping; Liu,Shujun; Byrd,John,C; Muthusamy,Natarajan; Garzon,Ramiro; Croce,Carlo,M; Marcucci,Guido; Chan,Kenneth,K. "Synthetic MicroRNA Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity." MOLECULAR PHARMACEUTICS. Vol. 9, no. 6. (June 2012.): 1638-1644.

O'Donnell,Margaret,R; Abboud,Camille,N; Altman,Jessica; Appelbaum,Frederick,R; Arber,Daniel,A; Attar,Eyal; Borate,Uma; Coutre,Steven,E; Damon,Lloyd,E; Goorha,Salil; Lancet,Jeffrey; Maness,Lori,J; Marcucci,Guido; Millenson,Michael,M; Moore,Joseph,O; Ravandi,Farhad; Shami,Paul,J; Smith,B,Douglas; Stone,Richard,M; Strickland,Stephen,A; Tallman,Martin,S; Wang,Eunice,S; Naganuma,Maoko; Gregory,Kristina,M. "Acute myeloid leukemia.." Journal of the National Comprehensive Cancer Network. Vol. 10, no. 8. (August 2012.): 984-1021.

Eisfeld,Ann-Kathrin; Marcucci,Guido; Liyanarachchi,Sandya; Doehner,Konstanze; Schwind,Sebastian; Maharry,Kati; Leffel,Benjamin; Doehner,Hartmut; Radmacher,Michael,D; Bloomfield,Clara,D; Tanner,Stephan,M; de la Chapelle,Albert. "Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 109, no. 17. (April 2012.): 6668-6673.

Zorko,Nicholas,A; Bernot,Kelsie,M; Whitman,Susan,P; Siebenaler,Ronald,F; Ahmed,Elshafa,H; Marcucci,Gabriele,G; Yanes,Daniel,A; McConnell,Kathleen,K; Mao,Charlene; Kalu,Chidimma; Zhang,Xiaoli; Jarjoura,David; Dorrance,Adrienne,M; Heerema,Nyla,A; Lee,Benjamin,H; Huang,Gang; Marcucci,Guido; Caligiuri,Michael,A. "Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias." BLOOD. Vol. 120, no. 5. (August 2012.): 1130-1136.

Zhang,Yue; Yan,Xiaomei; Sashida,Goro; Zhao,Xinghui; Rao,Yalan; Goyama,Susumu; Whitman,Susan,P; Zorko,Nicholas; Bernot,Kelsie; Conway,Rajeana,M; Witte,David; Wang,Qian-fei; Tenen,Daniel,G; Xiao,Zhijian; Marcucci,Guido; Mulloy,James,C; Grimes,H,Leighton; Caligiuri,Michael,A; Huang,Gang. "Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells." BLOOD. Vol. 120, no. 5. (August 2012.): 1118-1129.

Whitman,S,P; Caligiuri,M,A; Maharry,K; Radmacher,M,D; KOHLSCHMIDT,J; Becker,H; Mrozek,K; Wu,Y-Z; Schwind,S; Metzeler,K,H; Mendler,J,H; Wen,J; Baer,M,R; Powell,B,L; Carter,T,H; Kolitz,J,E; Wetzler,M; Carroll,A,J; Larson,R,A; Marcucci,G; Bloomfield,C,D. "The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia." LEUKEMIA. Vol. 26, no. 7. (July 2012.): 1713-1717.

Lozanski,Gerard; Ruppert,Amy,S; Heerema,Nyla,A; Lozanski,Arletta; Lucas,David,M; Gordon,Amber; Gribben,John,G; Morrison,Vicki,A; Rai,Kanti,M; Marcucci,Guido; Larson,Richard,A; Byrd,John,C. "Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study." LEUKEMIA & LYMPHOMA. Vol. 53, no. 9. (September 2012.): 1743-1748.

Walker,Alison; Marcucci,Guido. "Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.." Expert review of hematology. Vol. 5, no. 5. (October 2012.): 547-558.

Garzon,Ramiro; Marcucci,Guido. "Potential of microRNAs for cancer diagnostics, prognostication and therapy." CURRENT OPINION IN ONCOLOGY. Vol. 24, no. 6. (November 2012.): 655-659.

Sandhu,Sukhinder,K; Volinia,Stefano; Costinean,Stefan; Galasso,Marco; Neinast,Reid; Santhanam,Ramasamy; Parthun,Mark,R; Perrotti,Danilo; Marcucci,Guido; Garzon,Ramiro; Croce,Carlo,M. "miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E mu-miR-155 transgenic mouse model." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. Vol. 109, no. 49. (December 2012.): 20047-20052.

Alachkar,Houda; Xie,Zhiliang; Marcucci,Guido; Chan,Kenneth,K. "Determination of cellular uptake and intracellular levels of Cenersen (Aezea (R), EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells." JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. Vol. 71, (December 2012.): 228-232.

O'Donnell,Margaret,R; Abboud,Camille,N; Altman,Jessica; Appelbaum,Frederick,R; Arber,Daniel,A; Attar,Eyal; Borate,Uma; Coutre,Steven,E; Damon,Lloyd,E; Goorha,Salil; Lancet,Jeffrey; Maness,Lori,J; Marcucci,Guido; Millenson,Michael,M; Moore,Joseph,O; Ravandi,Farhad; Shami,Paul,J; Smith,B,Douglas; Stone,Richard,M; Strickland,Stephen,A; Tallman,Martin,S; Wang,Eunice,S; Naganuma,Maoko; Gregory,Kristina,M. "Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Vol. 10, no. 8. (August 2012.): 984-1021.

Yan,Pearlly; Frankhouser,David; Murphy,Mark; Tam,Hok-Hei; Rodriguez,Benjamin; Curfman,John; Trimarchi,Michael; Geyer,Susan; Wu,Yue-Zhong; Whitman,Susan,P; Metzeler,Klaus; Walker,Alison; Klisovic,Rebecca; Jacob,Samson; Grever,Michael,R; Byrd,John,C; Bloomfield,Clara,D; Garzon,Ramiro; Blum,William; Caligiuri,Michael,A; Bundschuh,Ralf; Marcucci,Guido. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia." BLOOD. Vol. 120, no. 12. (September 2012.): 2466-2474.

Ranganathan,Parvathi; Yu,Xueyan; Na,Caroline; Santhanam,Ramasamy; Shacham,Sharon; Kauffman,Michael; Walker,Alison; Klisovic,Rebecca; Blum,William; Caligiuri,Michael; Croce,Carlo,M; Marcucci,Guido; Garzon,Ramiro. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.

Wang,Hongyan; Chen,Ping; Wang,Jiang; Santhanam,Ramasamy; Aimiuwu,Josephine; Saradhi,U,VVijaya; Liu,Zhongfa; Schwind,Sebastian; Mims,Alice; Byrd,John,C; Grever,Michael,R; Villalona-Calero,Miguel,A; Klisovic,Rebecca; Walker,Alison; Garzon,Ramiro; Blum,William; Chan,Kenneth,K; Marcucci,Guido. "In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.." The AAPS journal. Vol. 15, no. 1. (January 2013.): 242-249.

Hickey,Christopher,J; Schwind,Sebastian; Radomska,Hanna,S; Dorrance,Adrienne,M; Santhanam,Ramasamy; Mishra,Anjali; Wu,Yue-Zhong; Alachkar,Houda; Maharry,Kati; Nicolet,Deedra; Mrózek,Krzysztof; Walker,Alison; Eiring,Anna,M; Whitman,Susan,P; Becker,Heiko; Perrotti,Danilo; Wu,Lai-Chu; Zhao,Xi; Fehniger,Todd,A; Vij,Ravi; Byrd,John,C; Blum,William; Lee,L,James; Caligiuri,Michael,A; Bloomfield,Clara,D; Garzon,Ramiro; Marcucci,Guido. "Lenalidomide-mediated enhanced translation of C/EBPa-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.." Blood. Vol. 121, no. 1. (January 2013.): 159-169.

Yu,Bo; Mao,Yicheng; Bai,Li-Yuan; Herman,Sarah,EM; Wang,Xinmei; Ramanunni,Asha; Jin,Yan; Mo,Xiaokui; Cheney,Carolyn; Chan,Kenneth,K; Jarjoura,David; Marcucci,Guido; Lee,Robert,J; Byrd,John,C; Lee,L,James; Muthusamy,Natarajan. "Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.." Blood. Vol. 121, no. 1. (January 2013.): 136-147.

Stock,Wendy; Johnson,Jeffrey,L; Stone,Richard,M; Kolitz,Jonathan,E; Powell,Bayard,L; Wetzler,Meir; Westervelt,Peter; Marcucci,Guido; DeAngelo,Daniel,J; Vardiman,James,W; Mcdonnell,Diane; Mrozek,Krzysztof; Bloomfield,Clara,D; Larson,Richard,A. "Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia Results of cancer and leukemia group B study 19802." CANCER. Vol. 119, no. 1. (January 2013.): 90-98.

 

Reference Works

January 1997 Marcucci G, Strout MP, Bloomfield CD, and Caligiuri MA."Detection of unique ALL 1 (MLL) fusion transcript in nomral human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts" . : 317a
January 1997 Marcucci G, Livak KJ, Bi WL, Strout MP, Bloomfield CD, and Caligiuri MA."Detection of the AML1/ETO transcript in patients with t(8;21)-associated AML using a novel "real time" quantitative RT-PCR assay" . : 390 a
January 1997 Marcucci G, Caligiuri MA, Oberkircher AR, and Bloomfield CD."Absence of minimal residual disease by reverse transcription polymerase chain reaction in CBF/MYH11-associated acute myeloid leukemia" . : 62a
January 1999 Willhauck M., Marcucci G, Dohner K, Schlenk RF, Lichter P, Bloomfield CD, Caligiuri MA, Dohner H."Quantitative detection of AML1/ETO transcripts in patients with t(8;21) associated AML by real time RT-PCR" . : 287a
January 1999 Marcucci G, Caligiuri MA, Maghraby EA, Archer K J, Dohner K, Schlenk RF, Dohner H and Bloomfield CD."Quantification of CBF/MYH11 transcripts in inv(16) acute myeloid leukemia (AML) by real time RT-PCR" . : 625
January 2000 Whitman SP, Stout MP, Marcucci G, Kees UR, Bloomfield CD, and Caligiuri MA."A criptic MLL (ALL1) partial non-tadem duplication gene rearrangement generates three distinct fusion transcripts is in B-cell acute lymphoblastic leukemia" .
January 2000 Vardiman J, Mrozek K, Anastasi J, Hoke E, Kolitz J, Carroll AJ, Caligiuri MA, Marcucci G, Larson R and Bloomfield CD."Cancer and Leukemia Group B Chicago IL Morpholoy and CBF/MYH11 in AML (CALGB Study 9621)" . : 165a
January 2000 Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Dohner K, Schlenk RF, Maghraby EA and Bloomfield CD."Quantification of minimal residual disease by real time RT-PCR CBF/MYH11 acute myeloid leukemia (AML)" .
January 2000 Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, and Caligiuri MA."A phase I trial of genase (G3139, Genta Inc), a BCL-2 antisense (AS), in a refactory (REF) or relapsed (REL) acute leukemia (AL)" . : 119a
January 2000 Farag SS, Fike S, Elder P, Marcucci G, Penza S, Mrozek E, Avalos B, and Copelan EA."Autologous and allogeneic hematopoietic stem cell transplantation in multiple myeloma: a single institution experience" . : 345b
January 2000 Farag SS, Fike S, Elder P, Marcucci G, Penza S, Mrozek E, Avalos B, and Copelan EA."Allogeneic hematopoietic cell transplantation in patients aged 50 years and over using conditioning regimens not containing total body irradiation (TBI)" . : 408 a
January 2000 Penza SL, Avalos B, Elder PJ, Fike S, Farag SS, Marcucci G, O'Donnell LC, Scholl MD, Whittaker B, Mrozek E, Bechtel TP, and Copelan EA."Predictive value of immunocytochemical detection of breast cancer cells and other factors in autotransplantation for breast cancer" . : 424a
January 2000 Copelan MA, Mrozek E, Penza SL, Elder PJ, Farag SS, Marcucci G, Bechtel TP, and Avalos BR."Delayed development of pulmonary toxicity syndrome following busulfan preparative therapy for allogeneic marrow transplantation" . : 346b
January 2000 Copelan EA, Penza SL, Elder PJ, Marcucci G, Farag SS, O'Donnell LC, Mrozek E, Fike S, Bechtel TP, Ezzone SA, Scholl MD, and Avalos BR."Therapy-related myelodysplasia and AML occur in infrequently following etoposide mobilization and autologous stem cell transplantation using radiation-free preparation" . : 402a
January 2001 Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas D, Chan KK, Young D, Didier LA, Bloomfield CD, Balcerzak SP, Frankel SR, Kraut EH, Grever MR and Caligiuri MA."Clinical and biological activity of Genasense (G3139, Genta, inc.), a BCL-2 antisense, in refractory (REF) or relapsed (REL) acute leukemia: a Phase I Study" . : 216b
January 2001 Marcucci G, Bloomfield CD, Balcerzak SP, Frankel SR, Maghraby EA, Lucas D, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Significant disease response to Genasense (Genta Inc)(GS), a BCL-2 antisense, in combination with chemotherapy in refractory (REF) or relapsed (REL) acute leukemia (AL)." . : 3681s
January 2001 Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Kourlas P, Lucas D, Chan KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Biologic Activity of G3139 (Genasense), a BCL-2 Antisense (AS), in Refractory (REF) or Relapsed (REL) Acute Leukemia (AL)." . : 288a
January 2001 Marcucci G, Archer KJ, Mrózek K, Carroll AJ, Sterling LJ, Edwards CG, Larson RA, Bloomfield CD."Abnormal karyotype during complete remission (CR) predicts short relapse-free survival (RF) in acute myeloid leukemia (AMLl): results from CALGB8461" . : 577a
January 2001 Frankel S, O’Brien S, Keating M, Andreeff M, Marcucci G, Gazitt Y, Klasa R, and Warrell R."Clincial and Biological Responses to Bcl-2 Antisense oligonucleotide therapy (Genasense ) in Hematologic Cancers" .
January 2001 Baiocchi R, Sekula T, Vourganti S, Nair V, Roychowdhury S, Parthun M, Nuovo G, Marcucci G, Byrd J, Grever M and Caligiuri M."Treatment of EBV-transformed B cell lines with depsipeptide results in the induction of a viral thymidine kinase and enhanced susceptibility to antiviral-induced apoptosis." .
January 2001 Maghraby E, Murphy T, Parthun M, Klisovic M, Anon J, Guimon M, Sklenar A, Archer K, Whitman S, Grever MR, Caligiuri MA, Byrd JC, Marcucci G."Depsipeptide (FR901228) Induces Lysine-Specific Histone Acetylation, Differentiation and Apoptosis in Acute Myeloid Leukemia Cells and Demonstrates Synergy with Decitabine" . : 86a
October 2001 Gore SD, Miller CB, Kaufmann S, Letendre L, Smith BD, Stock W, Marcucci G, and Karp JE."A single cycle of intensive consolidation therapy may be adequate for long term remissions in acute promyelocytic leukemia" .
January 2001 Porcu P, Farag S, Marcucci G, Avalos B, Rhoades C, Fisher B, Byrd JC, Grever MR, Caligiuri MA."Phase I Trial of Interleukin-2 (IL-2) and Rituximab in Patients (pts) with Relapsed or Refractory B-Cell Lymphoma (R/R-BCL)" . : 245b
January 2002 Tanner SM, Baldus CD, Austin JL, Whitman SP, Marcucci G, Caligiuri MA, de la Chapelle A, Archer KJ, Bloomfield CD."Expression of BAALC predicts adverse prognosis in adult de novo acute myeloid leukemia (AML) with normal cytogenetics: a Cancer and Leukemia Group B (CALGB) study" . : LB
January 2002 Xiao, J, Foraker, AB, Swaan, PW, Byrd, J, Marcucci, G, and Chan, KK."Depsipeptide FR90122 (NSC-630176) transport study in human intestinal epithelial Caco-2 cells" .
January 2002 Lin TS, Elder PJ, Penza SL, Avalos BR, Farag SS, Molina A, Mrozek E, Belt PS, Porcu P, Marcucci G, Byrd JC, Copelan EA."Autologous stem cell transplants result in better 5-year overall, but not progression-free, survival than allogeneic transplants in patients with indolent non-hodgkin’s lymphoma" . : 644a
January 2002 Bruner RJ, Marcucci G, Binkley P, Fischer B, Parthun M, Davis M, Xiao J, Chan K, Wright J, Grever MR, Byrd JC."A Phase I study to determine minimally effective pharmacologic dose (MEPD) of depsipeptide (FR901228) in selected hematologic malignancies" . : 265a
January 2002 Stone R, Yu D, Stock W, Hars V, Linker C, DeAngelo D, Shea T, Marcucci G, and Larson R."A Phase II Trial of Homoharringtonine (HHT) in Combination with Low-dose Cytarabine (lodac) via Continuous Intravenous Infusion (CIVI) for Newly Diagnosed Patients (pts) with Chronic Myeloid Leukemia (CML):CALGB19804" .
January 2002 Sooraj, LN, Marcucci G, Byrd JC, Bruner RJ, Fischer B, Hatton P, Grever MR, Binkley PF."Cardiovascular Response to Depsipeptide: Absence of Cardiotoxicity in Human Recipients" . : 378b
January 2002 Marcucci G, Stock W, Klisovic MI, Guimond M, Sher DA, Moran M, Zwiebel JA, Cataland SR, Kefauver C, Chan KK, Frankel SR, Grever MR, and Byrd, JC."In Vivo Activity Of Genasense™ (G3139) (GS), A Bcl-2 Antisense Oligonucleotide In Previously Untreated Patients (Pts) >60 Years With Acute Myeloid Leukemia (AML): Initial Report of a Phase I Study in Combination with Daunorubicin and Cytarabine" .
January 2002 Marcucci G, Bruner RJ, Binkley PF, Xia J, Chan KK, Parthun M, Davis M, Fischer B, Shank R, Moran M, Byrd JC, Grever M."Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Acute Myeloid Leukemia" . : 385 a
January 2003 Liu S, Shen T, Rush LJ, Klisovic MI, Whitman SP, Becknell B, Vukosavljevic T, Plass C, Byrd JC, and Marcucci G."AML1/ETO associates with DNMT1 in inducing transcriptional repression of the AML1-target gene Interleukin-3 (IL-3)" . : 218a
January 2003 Xiao J, Foraker AB, Swaan PW, Byrd JC, Marcucci G, and Chan KK."Cellular efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by both Pgp and MRPI" .
January 2003 Xiao J, Byrd J, Marcucci G, Grever M, Covey J, Wright J, Chan KK.."Disposition of Depsipeptide FX228 (FR901228, NSC 630176) in the Rat." .
January 2003 Whitman SP, Liu S, Klisovic MI, Vukosavljevic T, Guimond M, Rush LJ, Ruppert S, Strout MP, Becknell B, Dorrance AM, Bruner RJ, Plass C, Bloomfield CD, Marcucci G, and Caligiuri MA."Activation of the silenced MLL(ALL-1) wild-type allele in acute myeloid leukemia (AML) with the MLL partial tandem duplication results in enhancement of cell death" . : 221a
January 2003 Kolitz JE, George SL, Barrier R, Hoke E, Hurd D, Velez-Garcia E, Powell B, Marcucci G, Caligiuri MA, Vardiman JW, Bloomfield CD, and Larson RA."A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) < 60 years old with normal or unfavorable cytogenetics: results from CALGB 9621" . : 175a
January 2003 Kolitz JE, George SL, Barrier B, Hoke E, Hurd D, Velez-Garcia E, Powell B, Marcucci G, Baer M, Mrozek K, Carroll AJ, Edwards CG,* Caligiuri MA, Vardiman JW, Bloomfield CD, and Larson RA."Prospective treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HIDAC). Results from CALGB 9621" . : 176a
January 2003 Baldus CD, Tanner SM, Ruppert A, Whitman SP, Marcucci G, Caligiuri MA, Kolitz JE, Larson RA, de la Chapelle A, and Bloomfield CD."High BAALC expression identifies a new risk group of de novo Acute Myeloid Leukemia (AML) patients: A Cancer and Leukemia Group B (CALGB) Study" . : 263
January 2003 Anghelina M, Moldovan L, Klisovic M, Guimond M, Marcucci G, and Moldovan NI."Mobile Tie2 Positive Cells Incorporate Asymmetrically into the Arteriolar Side of Angiogenic Microvasculature" .
January 2003 Dai G, Marcucci G, Shen T, Caliguiri MA, Grever M, Byrd JC , Chan KK."Intracellular levels of Bcl-2 Antisense Phosphorothioate Oligodeoxynucleotide G3139 in leukemic cell lines and bone marrow of acute myeloid leukemia (AML) patients as measured by a novel fluorogenic ELISA assay" .
January 2003 Dai G, Chan KK, Hoyt D, Shen TS, Grever M, Caligiuri M, Byrd J, Marcucci G."A novel, highly sensitive fluorescence ELISA assay for Bcl-2 antisense phosphorothioate polynucleotide G3139 in biological matrices" .
May 2003 Marcucci G, Bruner RJ, Binkley PF, Xiao J, Chan KK, Parthun M, Davis M, Fischer B, Shank R, Moran M, Byrd JC and Grever MA."Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901228) in Acute Myeloid Leukemia (AML)" .
January 2003 Marcucci G, W Stock W, Zwiebel JA, Cataland SR, Dai G, Moran M, Lucas D, Liu S, Klisovic MI, Kefauver C, Green M, Chan KK, Frankel SR, Grever MR, and Byrd JC."Clinical Activity Of Genasense (GNS, Oblimersen Sodium), A Pro-Apoptotic To Bcl-2 Oligonucleotide, In Combination With Daunorubicin And Cytarabine: A Phase I Study In Previously Untreated Elderly Acute Myeloid Leukemia (AML)" . : 358
January 2003 Marcucci G, Dai G, Klisovic MI, Shen T, Liu S, Sher DA, Lucas D, Whitman SP, Vukosavljevic T, Zwiebel JA, Frankel SR, Grever MR, Stock W, Chan KK, and Byrd JC."Pharmacologic And Biologic Assessment Of Genasense (GNS, Oblimersen Sodium), A Pro-Apoptotic To Bcl-2 Oligonucleotide, In Combination With Daunorubicin And Cytarabine: A Phase I Study In Previously Untreated Elderly Acute Myeloid Leukemia (AML)" . : 874a
January 2003 Marcucci G, Dai G, Klisovic M, Chan KK, Grever M, Byrd JC."Pharmacologic and biologic assessment of Genasense, a pro-apoptotic to BCL-2 oligonucleotide, in combination with daunorubicin and cytarabine, a Phase I study in previously untreated elderly acute myeloid leukemia (AML)" . : 874a
January 2003 Bruner RJ, Marcucci G, Binkley P, Xiao J, Chan KK, Parthun M, Davis M, Fischer B, Shank R, Moran M, Grever MA and Byrd JC."Phase I Trial of the Histone Deacetylase Inhibitor Depsipeptide (FR901229) in Fludarabine Refractory Chronic Lymphocytic Leukemia" .
January 2003 Blum W, Bolwell BJ, Farag SS, Lin TS, Avalos BR, Penza SL, Marcucci G, Byrd JC, Kalaycio ME, Sobecks RM, Pohlman B, Brown S, Elder PJ, Copelan EA."Only Those Refractory AML Patients with Low Disease Burden Can Achieve Prolonged Leukemia-Free Survival with Conventional Unrelated Donor Transplantation." . : 488a
January 2003 Binkley PF, Sooraj LN, Marcucci G, Byrd JC, Bruner RJ, Fischer B, Hatton P, and Grever MR."Influence of Histone Deacetylase Inhibition, a Novel Therapeutic Target for Dilated Cardiomyopathy, on Cardiovascular Function" .
January 2004 Lucas D, Zhang L, Davis M, Su X, Sklenar A, Parthun M, Freitas M, Kitada S, Reed J, Marcucci G, Grever M, Byrd J."The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2" . : 766
January 2004 Blum W, Penza S, Farag S, Avalos B, Marcucci G, Lin T, Byrd J, Elder P, Copelan E."Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens" . : 364b
January 2004 Blum W, Blum K, Kefauver C, Moran M, Chan K, Byrd J, Cataland S, Grever M, Marcucci G."Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report" . : 215b
January 2004 Bloomfield CD, Ruppert AS, Mrozek K, Kolitz JE, Moore JO, Mayer RJ, Edwards CG, Sterling LJ, Vardiman JW, Carroll AJ, Pettenati MJ, Stamberg J, Byrd JC, Marcucci G, Larson RA."Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461" . : S84
January 2004 Baldus CD, Tanner Sm, Ruppert A, Whitman SP, Marcucci G, Caligiuri MA, Kolitz JE, Larson RA, de la Chapelle A, Bloomfield CD."High BAALC expression predicts adverse outcome in de novo acute myeloid leukemia (AML) patients: a CALGB study update" . : S13
January 2004 Dai G, Marcucci G, Shen T, Klisovic M, Liu S, Dai Z, Kefauver C, Sadee W, Grever M, and Chan KK."Pharmacokinetic and pharmacodynamic evaluation of Bcl-2 antisense G3139 in acute myeloid leukemia (AML) patients" .
January 2004 Xiao J, Huang Y, Dai Z, Sadee W, Foraker Z, Swaan P, Liu S, Marcucci G, Chen J, Byrd J, Wright J, Grever M, and Chan KK."Role of MDR1 and MRP1 in chemoresistance to the HDAC inhibitor depsipeptide FK228" .
January 2004 Wei X, Dai G, Marcucci G, Liu Z, Grever M, and Chan KK."Development and validation of an ultrasensitive two-Step hybridization-ELISA Assay for antisense oligonucleotide GTI2040 in plasma and human peripheral blood monouclear cells" .
January 2004 Marcucci G, Stock W, Dai G, Liu S, Klisovic R, Klisovic M, Sher D, Huynh L, Frankel S, Blum W, Larson R, Grever M, Byrd J, Chan K."Intracellular Levels of Oblimersen Sodium and Target Downregulation Correlates to Clinical Activity of bcl-2 Antisense in Acute Myeoid Leukemia (AML)" . : 331a
January 2004 Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel JA, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC."G3139, a bcl-2 antisense oligonucleotide, in AML" . : S93
January 2004 Marcucci G, Mrozek K, Ruppert A, Bloomfield CD."Abnormal cytogenetics at date of morphologic complete remission (CR) predicts short overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): results from Cancer and Leukemia B (CALGB) 8461" . : 559
November 2004 Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Mayer Rj, Pettenati MJ, Powell BL, Edwards CG, Sterling LJ, Vardiman JW, Schiffer CA, Carroll AJ, Larson RA, Bloomfield CD."t(8;21) acute myeloid leukemia (AML) differs from inv(16) AML in pretreatment characteristics, outcome, and prognostic factors predicting oucome: A Cancer and Leukemia Group B (CALGB) study" . : 556a
January 2005 Wei, X, Marcucci, G, Liu, S, Huynh, L, and Chan, KK."Pharmacokinetic and Pharmacodynamic Evaluation of GTI 2040, an Oligonucleotide antisense targeting ribonucleotide reductase, in patients with acute myeloid leukemia (AML)" .
January 2005 Marcucci G, Radmacher MD, Ruppert AS, Mrózek K, Kolitz JE, Whitman SP, Edwards CG, Vardiman JW, Caligiuri MA, Carroll AJ, Larson RA, Bloomfield CD."Independent validation of prognostic relevance of a previously reported gene-expression signature in acute myeloid leukemia (AML) with normal cytogenetics (NC): a Cancer and Leukemia Group B (CALGB) study." . : 101a
January 2005 Marcucci G, Radmacher M, Ruppert A, Mrózek K, Kolitz J,Whitman S, Edwards C, Vardiman J, Caligiuri MA, Carroll A, Larson R, Bloomfield CD."Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach" .
January 2005 Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrózek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A and Bloomfield CD."Overexpression of the ERG Gene is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study" . : 101a
January 2005 Marcucci G, Baldus C.D , Ruppert A, Radmacher M, Mrózek K, Whitman S, Kolitz J,Edwards C, J Vardiman, Powell B, Baer M, Moore J, Perrotti D, Caligiuri MA, Carroll A, Larson R, de la Chapelle A Bloomfield C."Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB)" .
January 2005 Liu, Z, Marcucci G, Byrd, J, Grever, M, Xiao, J, and Chan, KK."An API LC-MS-MS quantitation method for decitabine (5-aza-2’deoxycytidine) in rat and human plasma and itspharmacokinetics in rats" .
January 2005 Claudia D. Baldus, Michael Radmacher, Marcucci G, , Dieter Hoelzer, , Eckhard Thiel, , Clara D. Bloomfield, and Wolf-Karsten Hofmann."Co-Expression of BAALC with ERG, TCF4, and CD133 Indicates a Shared Pathway in Acute Myeloid and Lymphoblastic Leukemia" .
January 2005 Cheng, H, Liu, Z, Marcucci, G, Byrd, J, Grever, M, and Chan, KK."Quantification of valproic acid (VPA) and its metabolite 4-ene VPA in human plasma using HPLC-MS/MS" .
January 2005 Chan, KK, Wei, X, Dai, G, Liu, Z, Marcucci, G, and Grever M.."In vivo and metabolism and in vitro stability studies of GTI 2040, an oligonucleotide antisense, in patients with acute myeloid leukemia (AML)" .
January 2005 Chan KK, Wei X, Dai G, Liu Z, Marcucci G, Grever M."Metabolism of phosphorothioate antisense oligonucleotides" .
January 2005 Chan KK, Dai G, Wei X, Liu S, Liu Z, Grever MR, Marcucci, G."Pharmacokinetic/pharmacodynamic determinants in antisense therapy in patients with acute myeloid leukemia" .
April 2005 Wei X, Marcucci G, Dai G, Grever M, and Chan KK."Pharmacokinetics and intracellular levels of GTI 2040, an antisense olligonucleotide targeting ribonucleotide reductase, in patients with AML" .
January 2005 Neviani P, Santhanam R, Trotta R, Notari M, Uttam A, Blaser BW, Liu S, Roy DC, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D."Activation of PP2A: A novel mechanism for a potential targeted therapy of blast crisis and imatinib-resistant chronic myelogenous leukemia" . : 358
January 2005 Neviani P, Santhanam R, Trotta R, Notari M, Blaser B, Chang J, Liu S, Mao H, Oaks J, Roy D, Valtieri M, Rebecca Bruner-Klisovic, Michael A. Caligiuri, Clara D. Bloomfield, , Marcucci G and Danilo Perrotti."Resetting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML" .
January 2005 Neubauer A, Maharry K, Marcucci G, Mrózek K, Mayer RJ, Larson RA, Liu ET, Bloomfield CD."Patients(pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC)intensification: A Cancer and Leukemia Group B (CALGB) study" . : 535s
January 2005 Klisovic R, Blum W, Wei X, Liu S, Kefauver C, Huynh L, Zwiebel J, Byrd JC, Grever MR ,Marcucci G."A Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase (RNR) in Combination with High-Dose Cytarabine (HiDAC) in Relapsed or Refractory Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamic (PD) and Clinical Results" .
January 2005 Jonathan E. Kolitz, Stephen L. George, Marcucci G, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas Shea, Wendy Stock, Vera Hars, Eva Hoke, James W. Vardiman, Clara D. Bloomfield and Richard A. Larson A."Randomized. Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808" .
January 2005 Ji-Suk Chang, Mario Notari, Marcucci G, and Danilo Perrotti."BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases" .
January 2005 Blum W , Klisovic R , Liu S, Byrd JC, Liu Z, ,Chan KK, Kefauver C, L Huynh, Grever M, Marcucci G."Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity." .
October 2005 Chan KK, Dai G, Wei X , Liu S, Liu Z, Grever MR, and Marcucci G."Pharmacokinetic/Pharmacodynamic Determinants in Antisense Therapy in Patients with Acute Myeloid Leukemia" .
January 2006 Yu, J, Yu Li, Hackanson B, Wei M, Boyd Z, Yokohama A, Liu C, Trotta R, Mao HC, Becknell B, Jaung MS, Liu S, Byrd JC, Marcucci G, Plass C, Caligiuri MA."In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia" . : 627a
January 2006 Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Marcucci G, Gambacorti C, Roy DC, Caligiuri MA, Bloomfield CD, Chen CS, Byrd JC, Perrotti D."FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients" . : 151
January 2006 Blum W, Marcucci G, Devine H, Klisovic RB."Imatinib Mesylate-Induced Complete Cytogenetic Response in Acute Myeloid Leukemia with t(5;12)(q33;p13)" . : 11
January 2006 Blum W, Klisovic RB, Kefauver C, Johnson A, Phelps M, Dalton JT, Lucas D, Colevas AD, Grever M, Marcucci G, Byrd JC."Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics" . : 18s
April 2006 Liu Z, Xie Z, Liu S, Marcucci G, Chan, KK."Quantification of global DNA methylation levels in acute leukemia cell lines before and after decitabine treatment using a rapid, specific and sensitive LC-MS/MS method." .
November 2006 Wei X, Marcucci G, Huynh L, Blum W, Klisovic R, Kefauver C, Liu S, Dai G, Sun, J, Vukosavljevic T, Liu Z, Cheng H, Xie Z, Grever M, Chan KK."Population Pharmacokinetics (PK) of GTI-2040 in Patients with Acute Myeloid Leukemia (AML)" .
January 2006 Whitman, S Wen J, Muto G, Hackanson B, Yu L, Liu C, Sanfilippo J, Marcucci G, Rush L, Plass C, Caligiuri MA."The Tumor Suppressor Gene SLC5A8 Is Selectively Silenced in MLL Partial Tandem Duplication-Positive Acute Myeloid Leukemia with Normal Cytogenetics." . : 11
January 2006 Santhanam R, Neviani P, Eiring A, Oaks J, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Maracucci G, Passerini CG, Roy DC, Caligiuri MA, Bloomfield CD, Chen CS, Byrd JC, Perrotti D."FTY720, a new and alternative strategy for treating blast crisis CML and Ph1 ALL patients" . : 89a
January 2006 Marcucci G, Radmacher MD, Paschka P, Vukosavljevic T, Whitman SP, Ruppert AS, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD."MicroRNA (miR) Expression Signatures in Molecular Subsets of Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study" . : 3904
January 2006 Marcucci G, Klisovic RB, Wei W, Liu S Paschka P, Huynh L, Zwiebel JA, Byrd JC, Grever M, Chan K, Blum W."A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML)" . : 18s
January 2006 Sun J, Liu S, Yu J, Wei M, Mao C, Ding H, Kearney J, Huynh L, Paschka P, Wang D, Klisovic RB, Perrotti D, Chen C, Blum W, Marcucci G."Acute Myeloid Leukemia: Prognosis and Therapy in the Elderly and In Vitro Studies" . : 11
January 2006 Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Larson RA, Bloomfield CD."Mutations of KIT tyrosine kinase (TK) gene predict relapse in adult patients (pts) with core binding factor acute myeloid leukemia (CBF AML): A Cancer and Leukemia Group B (CALGB) study" . : 2
January 2006 Langer C, Ruppert AS, Radmacher MD, Whitman SP, Paschka P, Baldus C, Mrózek K, Kolitz JE, Marcucci G, Bloomfield CD."High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene expression signature in cytogenetically normal Acute Myeloid Leukemia (CN AML): A Cancer And Leukemia Group B Study" .
January 2006 Klisovic RB, Blum W, Hackanson B, Kefauver C, Liu S, Liu Z, Chan KK, Plass C, Wright JJ, Grever MR, Byrd JC, Marcucci G."Updated results of a phase I study of low dose decitabine and valproic acid in patients with acute myeloid leukemia (AML): gene re-expression, demethylation, and clinical response" .
January 2006 Baldus CD, Radmacher M, Marcucci G, Hoelzer D, Thiel E, Bloomfield CD, Hofmann WK."Co-expression of BAALC with ERG, TCF4 and CD133 indicates a shared pathway in acute myeloid and lymphoblastic leukemia" . : 13
January 2006 Ali NA, O'Brien JM, Blum W, Klisovic RB, Marcucci G, Phillips G, Marsh CB, Lemeshow, Stanley, Byrd, John C., Grever, Michael R."Hyperglycemia in Patients with Acute Myeloid Leukemia Is Associated with Increased Hospital Mortality" . : 11
January 2006 Liu S, Pang J, Yu J, Liu Z, Huynh L, Kearney J, Paschka P,. Klisovic RB, Baiocchi R, Blum W, Perrotti D, Marcucci G(Intr. by Guido Marcucci)."Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF-kB in AML1/ETO-Positive Cells. Session Type: Publication Only" . : 11
January 2007 Radmacher MD, Marcucci G, Paschka P, Vukosavljevic T, Whitman SP, Ruppert AS, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD."MicroRNA (miR) Expression Signatures in Molecular Subsets of Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study" . : 359S
January 2007 Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C.."An 86-probe gene expression signature can predict survival in AML with normal karyotype independently of FLT3 ITD and NPM1 mutation status - a collaborative study from the AMLCG and CALGB study groups" . : 183a
January 2007 Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz JE, Thakuri M, Carter T, Stuart RK, Larson RA."A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide, in untreated acute myeloid leukemia patients >60 years old." .
January 2007 Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrózek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD."High ERG expression predicts adverse outcome and refines molecular risk-based classification of cytogenetically normal (CN) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study" . : 580
January 2007 Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD."Gene and microRNA (miRNA) Expression Signatures and Prognostic Significance of CEBPA Mutations ABSTRACTS (Cont.)in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) with High-Risk Molecular Features: A Cancer and Leukemia Group B (CALGB) Study." . : 39a
April 2007 Liu Z., Liu S., Xie Z., Li C., Aimiuwu J., Chen P., Pang J., Marcucci G and Chan K.K."NF-kappaB Inhibitor Parthenolide Mediates DNA Demethylation and Histone Acetylation in Leukemia Cells." .
January 2007 Garzon Ramiro, Pichiorri Flavia, Marcucci Guido, Kornblau Steve, Andreeff Michael, Croce Carlo."MiRNA-29b Targets MCL-1 and Is Down-Regulated in Chemotherapy-Resistant Acute Myeloid Leukemia (AML)." .
January 2007 Garzon Ramiro, Liu Shujun, Fabbri Muller, Liu Zhongfa, Pang Jiuxia, Muthusamy Natarajan, Blum William, Chan Kenneth, Byrd John, Croce Carlos, Marcucci Guido."MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML)" .
January 2007 Corbacioglu A, Fröhling S, Paschka P, Marcucci G, Anhalt A, Urlbauer K, Krauter J, Larson R, Mrózek K, Ruppert AS, Ganser A, Caligiuri MA, Döhner H, Schlenk RF, Bloomfield CD, Döhner K."Acute myeloid leukemia (AML) with 9q aberrations occurring within a non-complex Karyotype is highly associated with CEBPA and NPM1 mutations – A joint analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB)" . : 234a
January 2007 Paschka P, Radmacher MD, Marcucci G, Ruppert AS, Vukosavljevic T, Whitman SP, Mrózek K, Liu C, Larson RA, Bloomfield C."Gene expression profiling improves outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML): A Cancer and Leukemia Group B (CALGB) study" . : 359S
January 2007 Paschka P, Marcucci G, Ruppert AS, Mrózek K, Whitman SP, Maharry K, Langer C, Baldus CD, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA. Bloomfield CD."Wilms Tumor 1 (WT1) Gene Mutations Predict Poor Outcome in Adults with Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): A Cancer and Leukemia Group B (CALGB) Study" . : 113a
January 2007 Paschka P, Marcucci G, Maharry K, Whitman SP, Ruppert AS, Vukosavljevic T, Mrózek K, Powell BL, Kolitz JE, Larson RA, Bloomfield CD."Prognostic Impact of NOMI Mutations in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML) is Adversely Affected by High Expression of the ERG Gene: A Cancer and Leukemia Group B (CALGB) Study. Oral presentation to EHA 2007" .
January 2007 Hackanson B, Bennett K, Brena R, Jiang J, Maharry K, Whitman SP, Schmittgen, TD, Luebbert M, Marcucci G, Bloomfield CD, Plass C."Epigenetic Control of CCAAT/Enhancer Binding Protein α (C/EBPα) Expression in Acute Myeloid Leukemia" . : 630a
January 2007 Whitman SP, Ruppert AS, Radmacher MD, Mrózek K, Paschka P, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD."FLT3 D835/I836 mutations predict worse disease-free survival (DFS) in younger adults with cytogenetically normal acute myeloid leukemia (CN AML) without FLT3 internal tandem duplications (ITD): A Cancer and Leukemia Group B (CALGB) study" . : 573S
January 2007 Whitman SP, Ruppert AS, Marcucci G, Mrózek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, Carroll AJ, Kolitz JE, Larson RA, Caligiuri MA, Bloomfield CD."Improved clinical outcome of cytogenetically normal acute myeloid leukemia with the MLL partial tandem duplication: A Cancer and Leukemia Group B (CALGB) study" . : 580
January 2008 Xie Z, Liu Z, Chiu M, Dunkerson S, Muthusamy N, Garzon R, Liu L, Croce C, Byrd J.C, Marcucci G, Chan KK."A validated ultrasensitive hybridization-ELISA assay for synthetic microRNAs in mouse plasma and human leukemia cells and its mouse pharmacokinetics" .
January 2008 Langer C, Maharry K, Mrózek K, Paschka P, Whitman SP, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD."Low Meningioma 1 (MN1) gene expression to predict outcome in cytogenetically normal acute myeloid leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) study" . : 374S
January 2008 Blum W, Andritsos L, Johnson AJ, Klisovic R, Kefauver C, Devine S, Marcucci G, Byrd JC."Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dos" .
June 2009 Becker H, Marcucci G, Maharry K, Margeson D, Radmacher MD, Whitman SP, Mrózek K, Baer MR, Larson RA, Bloomfield CD.."NPM1 mutations as an independent prognosticator for older cytogenetically normal acute myeloid leukemia (CN AML)." .
November 2009 Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf LJ, Humphries K, Grever MR, Devine SM, Byrd JC, and Marcucci G.."Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)." . : 2065
November 2009 Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Whitman SP, Paschka P, Margeson D, Wu YZ, Schwind S, Langer MD, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson, MD, Bloomfield CD."Comparison of Clinical and Biologic Significance of WT1 Mutations in Populations of Older (≥60 years[y]) and Younger (<60 y) Adult Patients (Pts) with Cytogenetically Normal (CN) De Novo Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study." . : 326
November 2009 Attar EC, Maharry K, Mrózek K, Radmacher MD, Whitman SP, Paschka P, Langer C, Holland KB, Powell BL, Kolitz JE, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD.."Increased Expression of Macrophage Migration Inhibitory Factor (MIF) Receptor CD74 Is Associated with Inferior Outcome in Younger Patients (Pts) with Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study." . : 1616
November 2009 Hickey C, Schwind S, Becker H, Alachkar H, Garzon R, Wu Y-Z, Liu S, Perrotti D, and Marcucci G.."MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells" . : 938
November 2009 Hassane D, Balys M, Marcucci G, Byrd JC, Jordan CT, and Guzman ML.."Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML)." . : Abstract 1070
November 2009 Harb J, Neviani P, Huettner C, Marcucci G, and Perrotti D.."BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells." . : Abstract 191
November 2009 Farag S, Maharry K, Perez WS, Zhang MJ, DiPersio JF, Bunjes D, Marcucci G, Baer MR, Larson RA, Tallman M, Bloomfield CD, Weisdorf DJ.."Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Compared to Chemotherapy Only in Acute Myeloid Leukemia (AML) Patients 60 Years and Older: A Center for International Blood and Marrow Transplantation Research (CIBMTR)/Cancer and Leukemia Group B (CALGB) Study." . : abstract #22879
November 2009 Eiring AM, Harb J, Neviani P, Oaks J, Liu S, Spizzo R, Schwind S, Santhanam R, Hickey C, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Sr., Huettner C, Bhatia R, Roy D-C, Liebhaber S, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, and Perrotti D.."Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors." . : 855
November 2009 Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic RB, Garzon R, Grever MR, Villalona-Calero M, Byrd JC, Chan KK, and Marcucci G."Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine." . : 3782
November 2009 Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang X, Schaaf L, Schwind S, Becker H, Liu S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, and Blum W.."Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia." . : 841
November 2009 Whitman SP, Maharry K, Radmacher MD, Mrozek K, Margeson D, Holland KB, Becker H, Wu YZ, Schwind S, Baer MR, Powell BL, Stone RM, Carroll JA, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.."Adverse Prognostic Impact of FLT3 Internal Tandem Duplication (ITD) Is Age-Associated in Older [≥60 Years (Y)] De Novo cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Patients (Pts): a Cancer and Leukemia Group B (CALGB) Study." . : 1579
November 2009 Smooha G, Birger Y, Goldberg L, Jacob-Hirsch J, Amariglia N, Rechavi G, Levanon D, Groner Y, Taragan A, Kloog Y, Wen J, Crispino J, Radmacher MD, Marcucci G, Bloomfield CD, Izraeli S.."Modeling and Targeting ERG-induced Acute Myeloid Leukemia (AML)." . : 475
June 2009 Schwind S, Marcucci G, Maharry K, Radmacher MD, Whitman SP, Paschka P, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD.."MicroRNA 181a (miR-181a) expression as a prognosticator in cytogenetically normal acute myeloid leukemia (CN AML)." . : 7001
June 2009 Marcucci G, Maharry K, Whitman SP, Paschka P, Baldus CD, Langer C, Mrózek K, Kolitz JE, Larson RA, Bloomfield CD.."Improving the molecular risk classification for younger (<60 years) de novo cytogenetically normal acute myeloid leukemia (CN AML) patients (pts)." . : 7002
November 2009 Schwind S, Marcucci G, Maharry K, Mrozek K, Radmacher MD, Holland KB, Becher H, Whitman SP, Wu YZ, Baer MR, Powell BL, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD.."Aberrant Gene Expression of BAALC and ERG in Older [≥60 Years (y)] De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML): A Cancer and Leukemia Group B (CALGB) Study." . : 214
November 2009 Payton JE, Marcucci G, Radmacher MD, Maharry K, Langer C, Baldus CD, Bloomfield CD, Ley TJ.."Multiplexed Digital Quantification of mRNA Abundance: a Highly Reproducible, PCR–independent Assessment of BAALC, ERG, and MN1 mRNA Levels in Acute Myeloid Leukemia (AML) Bone Marrow (BM) and Peripheral Blood (PB) Samples." . : 1599
November 2009 Oaks J, Neviani P, Mukhopadhyay A, Santhanam R, Ma Y, Mao C, Marcucci G, Chen SH, Cortes J, Caligiuri MA, Hokland P, Huettner C, Koschmieder S, Cancelas J, Briesewitz R, Bhatia R, Roy DC, Ogretmen B, and Perrotti D.."FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(–) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor." . : 3259
November 2009 Mrozek K, Holland KB, Pettanati MJ, Maharry K, Marcucci G, Baer MR, Kolitz JE, Margeson D, Edwards CG, Carroll AJ, Larson RA, Bloomfield CD.."Prognostic Significance of Unbalanced Chromosome Abnormalities Used by 2008 World Health Organization (WHO) Classification to Define “Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes” in Adults: a Cancer and Leukemia Group B (CALGB) Study." . : 2602
November 2009 Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu Y-Z, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, Byrd JC, Perrotti D, Garzon R, and Marcucci G.."Evidence of MicroRNA-29b and Sp1/NF B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications." . : 3782
November 2009 Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu Y-Z, Hickey C, Yu J, Mishra A, Becker H, Li C, Briesewitz R, Baiocchi RA, Chan KK, Caligiuri MA, Byrd JC, Perrotti D, Garzon R, and Marcucci G.."MicroRNA-29b and Sp1/NF B-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications." . : 841
December 2009 Havelange V, Volinia S, Andreeff M, Marcucci G, Croce CM, and Garzon R.."Functional Implications of miRNAs in Acute Myeloid Leukemia (AML) by miRNA-mRNA Expression Profiling." . : 766
June 2010 Mishra A, Liu S, Pang J, Yang X, Garzon R, Lee R, Marcucci G, and Caligiuri M.."Interleukin (IL)-15 and miR-29b leukemogenic interplay: a novel therapeutic target for large granular lymphocytic leukemia." . : (Poster Presentation) (First Award Winner)
June 2010 Zorko N, Whitman S, Dorrance A, Liu S, Chen K, Zou X, Mao C, Wen J, Kalu, Jamieson R, Lee B, Gilliland D, Marcucci G, and Caligiuri M.."A novel murine model of leukemogenesis with Mll PTD and Flt3 ITD knock-ins." . : (Poster Presentation)
June 2010 You J, Liu S, Marcucci G, Freitas M.."Optimization of Phosphotyrosine Protein Enrichment for the Identification and Validation of Drug Targets in Acute Myeloid Leukemia" . : Poster Presentation
June 2010 Yan F, Alinari L, Lustberg M, Martin LK, Nowicki O, Wu X, Yu B, Gordon K, Wolfson A, Ryu J, Kaur B, Kwon CH, Lawler S, Nuovo G, Liu S, Marcucci G, Byrd J, Chiocca A, Baiocchi R.."Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas." .
June 2010 Bernot K, Zorko N, Liu S, Santhanam R, Whitman S, Dorrance A, Chen K, Zou X, Mao C, Wen J, Lee B, Gilliland D, Marcucci G, Caligiuri M.."Personalized medicine in Acute Myeloid Leukemia: Targeting epigenetics and tyrosine kinases in a transplant mouse model of Mll-PTD and Flt3 ITD leukemia." . : Poster Presentation
June 2010 Alachkar H, Liu S, Schwind S, Becker H, Metzeler K, Hickey C, Pang J, Whitman S, Chan K, Garzon R, Lucas D, Perrotti D, Wu LC, Grever M, Kinghorn D, Marcucci G.."The natural product silvestrol decreases oncogenic FLT3 and miR-155 levels in FLT3-ITD positive Acute Myeloid Leukemia (AML) cells." .

Presentations

"Detection of the AML1/ETO transcript in patients with t(8;21)-associated AML using a novel "real time" Methodology." Presented at American Society of Hematology, Miami, FL. (December 1997)

"Quantification of CBF/MYH11 transcripts in inv(16) acute myeloid leukemia (AML) by real time RT-PCR." Presented at American Society of Hematology, Miami, FL. (December 1999)

"Innovation in biological therapy of cancer 2000: Quantification of minimal residual disease by real time RT-PCR in CBFbeta/MYH11 acute myeloid leukemia." Presented at Third Annual regional Cancer Center Consortium, Hershey, PA. (February 2000)

"BCL-2 antisense strategies in refractory (REF) or relapsed (REL) and acute leukemia (AL)." Presented at National Cancer Institute-Cancer Therapy Evaluation Program, Bethesda, MD. (September 2000)

"Depsipeptide (FR901220) in selected hematologic malignancies." Presented at Nation Cancer Institution-Cancer Therapy Evaluation Program, Bethesda, MD. (March 2002)

"DNA methylation and chromatine remodeling in leukemia:the physician prospective." Presented at Ohio State Molecular Biology and Cancer Genetics Program, Columbus, OH. (May 2002)

"A phase I study of G3139 in combination with cytarabine and daunorubicin in untreated patients with acute myeloid leukemia (AML)>60 years of age." Presented at NCI-CTEP Phase I Meeting Cancer Therapy Session, Bethesda, MD. (September 2003)

"Depsipeptide in acute myeloid leukemia." Presented at John Hopkins and NCI Histone deacetylase and Chromatin Remodeling workshop, Baltimore, MD. (January 2003)

"Antisense strategy in AML." Presented at MD Anderson Cancer Center, Houston, TX. (October 2003)

"Chromatin remodeling and histone deacetylase inhibitors in AML." Presented at Chemotherapy Foundation Symposium XXII, New York, NY. (November 2004)

"Abnormal cytogenetics at date of morpholyic complete remission (CR) predicts shorts overall (OS) Disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML) result from cancer and Leukemia Group B." Presented at American Society of Clinical Oncology, New Orleans, LA. (June 2004)

"G3139 antisense treatment in acute leukemia." Presented at International Symposium Acute Leukemia X, Munich, DE|DEU. (February 2004)

"Pharmacologic Modulation of Epigenetic changes in AML." Presented at American Society of Hematology Corporate Friday Satellite Symposium, San Diego, CA. (December 2004)

"Elucidation of Molecular Mechanisms by which inflammatory and anti-inflammatory monokines regulate interferon (INF)." Presented at American Society of Hematology, San Diego, CA. (December 2004)

"Core binding factor AML: Is It time to change therapeutic strategies." Presented at Mt Siani School of Medicine-Grand Rounds, New York, NY. (March 2005)

"Core Binding Factor Acute Myeloid Leukemia: Is It Time to Change Therapeutic strategies." Presented at Central Society for Clinical Research Midwestern Section American Federation for Medical Research, Chicago, IL. (April 2005)

"Leukemia, Myelodysplasia and Transplantation." Presented at American Society of Clinical Oncology, Atlanta, GA. (June 2006)

"Combining epigenetic approaches:results results with histone deacetylases and hypomethylating agents." Presented at American Society of Cinical Oncology, Atlanta, GA. (June 2006)

"Combining Epigenetic approaches:recent results with histone deacetylase inhibitors and hypomethylating agents." Presented at American Society of Oncology Symposium, New York, NY. (October 2006)

"Genasense/GTI 2040." Presented at OSUCCC Pediatric Oncology Program, Wilmington, OH. (December 2006)

"Which new agents have the most promise and why." Presented at Acute Leukemia Forum, San Francisco, CA. (March 2007)

"Advances and controversies i the biology and therapy of acute myelogenous leukemia and myelodysplasia, which new agents have the most promis and why?." Presented at International Acute Leukemia Forum, San Franciso, CA. (March 2007)

"Phase III randomized trial of intensive induction and consolidation chemotherapy +/- oblimersen (Genasense; G3139), a proapoptotic Bcl-2 antisense oligonucleotide, in untreated AML patients >60 years and high ERG expression predicts adverse out come and refines molecular risk-based classification of cytogenetically normal AML." Presented at Cancer and Leukemia Group B Summer meeting, Baltimore, MD. (June 2007)

"Epigenetics of malignant hematopoiesis." Presented at The XXIII Symposium of International Association for Comparative Research on Leukemia and Related Diseases, Frieburg, DE|DEU. (September 2007)

"The role of post-consolidation therapy in AML." Presented at American Society of Hematology, . (December 2007)

"Gene Mutations in AML." Presented at American Society of Hematology, Atlanta, GA. (December 2007)

"Novel approaches to target abberrant epigenetics in AML." Presented at Developmental Cancer Therapeutics Program, Duarte, CA. (November 2007)

"The Molecular Characterization of AML." Presented at Fourth Annual Oncology Congress, San Francisco, CA. (September 2008)

"Targeting abberrant epigenetics in acute myeloid leukemia: new therapeutic strategies." Presented at The Ohio State Medical Center, Comprehensive Cancer Center: Grand Rounds, Columbus, OH. (February 2008)

"Targeting abberrant epigenetics in acute myeloid leukemia:new therapeutic strategies." Presented at Cancer Cell Biology Seminar, Morgantown, WV. (March 2008)

"Management of AML with normal cytogenetics." Presented at Bone and Marrow Transplant Group of Georgia, Atlanta, GA. (March 2008)

"Prognostic molecular markers in AML." Presented at MD Anderson Hospital, Houston, TX. (May 2008)

"Clinical Application of Epigenomic Therapy." Presented at New York Cancer Consortium Third Annual Developmental Therapeutics Symposium, New York City, NY. (May 2008)

"MicroRNA profiling." Presented at ESH-EHA Scientific Workshop on Molecular Prognostic Markers in Acute Myeloid Leukemia, Mandelieu, FR|FRA. (October 2008)

"Biology and Prognostic Significance." Presented at ESH-EHA Scientific Workshop on Molecular Prognostic Markers in Acute Myeloid Leukemia, Mandelieu, FR|FRA. (October 2008)

"Recent Studies of Pathophysiology of AML: Implications for Targeted Therapies." Presented at American Association for Cancer Research, Denver, CO. (April 2009)

"Session: Leukemia, Myelodysplasia and Transplantation." Presented at Annual American Society of Clinical Oncology Meeting, Orlando, FL. (June 2009)

"Hematology-in-focus MicroRNA in leukemia." Presented at European Hematology Association, 14th Congress. Berlin, Germany,, Berlin, DE|DEU. (June 2009)

"MicroRNA 29B functions in Acute Leukemia." Presented at European Hematology Association, 14th Congress, Berlin, DE|DEU. (June 2009)

"Session: Leukemia, Myelodysplaia and Transplantation." Presented at Annual American Society of Clinical Oncology, New Orleans, LA. (December 2009)

"MicroRNA’s: New Paradign." Presented at Annual American Society of Clinical Oncology 2009, New Orleans, LA. (December 2009)

"MicroRNA's: New Paradigm." Presented at Annual American Society of Clinical Oncology Meeting, Orlando, FL. (May 2009)

"Decitabine with Valproic Acid and Other Combinations in Acute Myeloid Leukemia." Presented at International Conference in Differentiation Therapy 2009, Vienna, VA. (November 2009)

"Interleukin (IL)-15 and miR-29b leukemogenic interplay: a novel therapeutic target for large granular lymphocytic leukemia." Presented at 12th Annual Scientific Meeting of OSU Comprehensive Cancer Center, COlumbus, OH. (January 2010)

"Personalized medicine in Acute Myeloid Leukemia: Targeting epigenetics and tyrosine kinases in a transplant mouse model of Mll-PTD and Flt3 ITD leukemia." Presented at 12th Annual Scientific Meeting of OSU Comprehensive Cancer Center, Columbus, OH. (January 2010)

"A novel murine model of leukemogenesis with Mll PTD and Flt3 ITD knock-ins. leukemia." Presented at 12th Annual Scientific Meeting of OSU Comprehensive Cancer Center, Columbus, OH. (January 2010)

"Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study.." Presented at ASH 2010, Orlando, FL, US|USA. (December 2010)

"BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment. Abstract 515.." Presented at ASH 2010, Orlando, FL, US|USA. (December 2010)

"Targeting microRNAs in AML." Presented at The Ohio State University, Experimental Therapeutics Programs, Columbus, OH. (September 2010)

"Micro RNA and Molecular Profiling in AML --- Is it Relevant?." Presented at Hematologic Malignancies 2010, Houston, TX. (October 2010)

"Molecular Prognostic Factors with AML." Presented at 2010 BMT Tandem Meetings, Orlando, FL, US|USA. (February 2010)

"Micro RNA in AML and CLL. What does it mean?." Presented at ASCO Annual Meeting, Education Session, Chicago, IL. (June 2010)

"Biologic and therapeutic implications of prognostic molecular markers in acute myeloid leukemia." Presented at M.D. Anderson Cancer Center, Houston, TX. (August 2010)

"Biologic and therapeutic implications of prognostic molecular markers in acute myeloid leukemia." Presented at Emory University, Grand Rounds, Atlanta, GA. (August 2010)

"New Molecular Markers in AML --- Can They Be Used Clinically?." Presented at ASH Review, Dearborn, MI, US|USA. (January 2010)

"Acute Promyelocytic Leukemia." Presented at The Ohio State University, Hematology/Oncology Basic Science & Clinical Lecture Series, Columbus, OH. (April 2010)

"Biologic and therapeutic implications of prognostic molecular markers in acute myeloid leukemia." Presented at Memorial Sloan-Kettering Cancer Center Grand Rounds, New York, NY, US|USA. (April 2010)

 

Professional Activities

2003 - present William Blum - Young Faculty. The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute. Columbus, OH.